condition found
Source: HalifaxProj (inhibit) |
Type: |
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer. ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations. However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS. "Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways." "During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity." "ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−". "Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules." Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea. Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells." Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers. -It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis. Note: Products that may raise ROS can be found using this database, by: Filtering on the target of ROS, and selecting the Effect Direction of ↑ Targets to raise ROS (to kill cancer cells): • NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS. -Targeting NOX enzymes can increase ROS levels and induce cancer cell death. -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS • Mitochondrial complex I: Inhibiting can increase ROS production • P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes) • Nrf2: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels • Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels • Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels • SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels • PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels • HIF-1α: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS • Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production. -Inhibiting fatty acid oxidation can increase ROS levels • ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels • Autophagy: process by which cells recycle damaged organelles and proteins. -Inhibiting autophagy can increase ROS levels and induce cancer cell death. • KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes. -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death. • DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels • PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels • SIRT1:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels • AMPK: regulates energy metabolism and can increase ROS levels when activated. • mTOR: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels • HSP90: regulates protein folding and can increase ROS levels when inhibited. • Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels • Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS. -Increasing lipid peroxidation can increase ROS levels • Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation. -Increasing ferroptosis can increase ROS levels • Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability. -Opening the mPTP can increase ROS levels • BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited. • Caspase-independent cell death: a form of cell death that is regulated by ROS. -Increasing caspase-independent cell death can increase ROS levels • DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS • Epigenetic regulation: process by which gene expression is regulated. -Increasing epigenetic regulation can increase ROS levels -PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS) ProOxidant Strategy:(inhibit the Melavonate Pathway (likely will also inhibit GPx) -HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more -Atorvastatin typically 40-80mg/day -Dipyridamole typically 200mg 2x/day -Lycopene typically 100mg/day range Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy |
3423- | ,  |   | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
- | Review, | Var, | NA |
2327- | 2DG,  |   | 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents |
- | Review, | Var, | NA |
1339- | 2DG,  | Cisplatin,  |   | 2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells |
- | in-vitro, | HNSCC, | FaDu |
1337- | 2DG,  | Rad,  |   | 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer |
- | in-vivo, | NA, | NA |
1336- | 2DG,  |   | 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells |
- | in-vitro, | GBM, | SK-N-SH |
1341- | 3BP,  |   | The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate |
- | Review, | NA, | NA |
3453- | 5-ALA,  |   | The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis |
- | in-vitro, | Lung, | A549 |
252- | Ajoene,  |   | Ajoene, a Compound of Garlic, Induces Apoptosis in Human Promyeloleukemic Cells, Accompanied by Generation of Reactive Oxygen Species and Activation of Nuclear Factor κB |
- | in-vitro, | AML, | HL-60 |
233- | AL,  | 5-FU,  |   | Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway |
- | in-vivo, | Liver, | NA |
234- | AL,  |   | Allicin Induces Anti-human Liver Cancer Cells through the p53 Gene Modulating Apoptosis and Autophagy |
- | in-vitro, | HCC, | Hep3B |
235- | AL,  |   | Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway |
- | in-vitro, | GBM, | U87MG |
236- | AL,  |   | Allicin: Chemistry and Biological Properties |
- | Analysis, | NA, | NA |
239- | AL,  |   | Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways |
- | in-vitro, | GC, | SGC-7901 |
248- | AL,  |   | Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway |
- | in-vitro, | GBM, | U87MG |
257- | AL,  | Cisplatin,  |   | Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors |
- | in-vitro, | NSCLC, | A549 |
254- | AL,  |   | Allicin and Cancer Hallmarks |
- | Review, | Var, | NA |
231- | AL,  |   | Molecular Docking Studies with Garlic Phytochemical Constituents to Inhibit the Human EGFR Protein for Lung Cancer Therapy |
- | Analysis, | Lung, | NA |
1069- | AL,  |   | Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling |
- | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | Nor, | Het-1A |
2655- | AL,  |   | Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities |
- | Review, | GC, | NA |
2646- | AL,  |   | Anti-Cancer Potential of Homemade Fresh Garlic Extract Is Related to Increased Endoplasmic Reticulum Stress |
- | in-vitro, | Pca, | DU145 | - | in-vitro, | Melanoma, | RPMI-8226 |
2648- | AL,  |   | Allicin Inhibits Osteosarcoma Growth by Promoting Oxidative Stress and Autophagy via the Inactivation of the lncRNA MALAT1-miR-376a-Wnt/β-Catenin Signaling Pathway |
- | in-vitro, | OS, | SaOS2 | - | in-vivo, | OS, | NA |
2658- | AL,  |   | The Toxic Effect Ways of Allicin on Different Cell Lines |
- | Review, | Var, | NA |
2660- | AL,  |   | Allicin: A review of its important pharmacological activities |
- | Review, | AD, | NA | - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
2666- | AL,  |   | Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals |
- | Review, | Var, | NA |
2663- | AL,  |   | Therapeutic Effect of Allicin on Glioblastoma |
- | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
2000- | AL,  |   | Exploring the ROS-mediated anti-cancer potential in human triple-negative breast cancer by garlic bulb extract: A source of therapeutically active compounds |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | NA |
1235- | ALA,  | Cisplatin,  |   | α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway |
- | in-vitro, | Nor, | HEI-OC1 | - | ex-vivo, | NA, | NA |
297- | ALA,  |   | Insights on the Use of α-Lipoic Acid for Therapeutic Purposes |
- | Review, | BC, | SkBr3 | - | Review, | neuroblastoma, | SK-N-SH | - | Review, | AD, | NA |
304- | ALA,  |   | alpha-Lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2-*-generation |
- | in-vitro, | Colon, | HT-29 |
279- | ALA,  |   | Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
281- | ALA,  |   | Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation |
- | in-vitro, | Lung, | H460 |
278- | ALA,  |   | The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment |
- | Review, | NA, | NA |
277- | ALA,  |   | α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation |
- | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B |
267- | ALA,  |   | α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis Effect of Lung Cancer Cells |
- | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | PC9 |
266- | ALA,  |   | Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death |
- | in-vitro, | Ovarian, | IGROV1 |
265- | ALA,  |   | Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
264- | ALA,  |   | α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells |
- | in-vitro, | HCC, | FaO |
259- | ALA,  |   | Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells |
- | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | FaO |
3443- | ALA,  |   | Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention |
- | Review, | Var, | NA | - | Review, | AD, | NA |
3442- | ALA,  |   | α‑lipoic acid modulates prostate cancer cell growth and bone cell differentiation |
- | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | 3T3 |
3438- | ALA,  |   | The Potent Antioxidant Alpha Lipoic Acid |
- | Review, | NA, | NA | - | Review, | AD, | NA |
- | in-vitro, | BC, | MCF-7 |
3434- | ALA,  |   | Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
3454- | ALA,  |   | Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
3541- | ALA,  |   | Insights on alpha lipoic and dihydrolipoic acids as promising scavengers of oxidative stress and possible chelators in mercury toxicology |
- | Review, | Var, | NA |
1351- | And,  | MEL,  |   | Impact of Andrographolide and Melatonin Combinatorial Drug Therapy on Metastatic Colon Cancer Cells and Organoids |
- | in-vitro, | CRC, | T84 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | DLD1 |
1352- | And,  |   | Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy |
- | in-vitro, | AML, | K562 |
1350- | And,  | Cisplatin,  |   | Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer |
- | in-vitro, | Colon, | NA |
1348- | And,  |   | Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vivo, | NA, | NA |
1349- | And,  |   | Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction |
- | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H1650 |
1354- | And,  |   | Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer |
- | in-vitro, | PC, | NA | - | in-vivo, | PC, | NA |
586- | Api,  | 5-FU,  |   | 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma |
- | in-vivo, | HCC, | NA |
171- | Api,  |   | Apigenin in cancer therapy: anti-cancer effects and mechanisms of action |
- | Review, | Var, | NA |
416- | Api,  |   | In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma |
- | vitro+vivo, | NA, | NA |
313- | Api,  |   | Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells |
- | in-vitro, | Thyroid, | BCPAP |
2593- | Api,  |   | Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo |
- | in-vivo, | BC, | 4T1 |
2632- | Api,  |   | Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress |
- | in-vitro, | EC, | NA |
2640- | Api,  |   | Apigenin: A Promising Molecule for Cancer Prevention |
- | Review, | Var, | NA |
2639- | Api,  |   | Plant flavone apigenin: An emerging anticancer agent |
- | Review, | Var, | NA |
2634- | Api,  |   | Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells |
- | in-vitro, | CRC, | HCT116 |
2633- | Api,  |   | Apigenin induces ROS-dependent apoptosis and ER stress in human endometriosis cells |
- | in-vitro, | EC, | NA |
2631- | Api,  |   | Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells |
- | in-vivo, | GC, | NA | - | in-vitro, | GC, | AGS |
1999- | Api,  | doxoR,  |   | Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation |
- | in-vitro, | Nor, | NRK52E | - | in-vitro, | Nor, | MPC5 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
1537- | Api,  |   | Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer |
- | Review, | PC, | NA |
1536- | Api,  |   | Apigenin causes necroptosis by inducing ROS accumulation, mitochondrial dysfunction, and ATP depletion in malignant mesothelioma cells |
- | in-vitro, | MM, | MSTO-211H | - | in-vitro, | MM, | H2452 |
1564- | Api,  |   | Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation |
- | in-vitro, | Pca, | 22Rv1 | - | in-vivo, | NA, | NA |
1547- | Api,  |   | Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading |
- | Review, | NA, | NA |
1565- | Api,  |   | Apigenin-7-glucoside induces apoptosis and ROS accumulation in lung cancer cells, and inhibits PI3K/Akt/mTOR pathway |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H1975 |
1563- | Api,  | MET,  |   | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
- | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
1076- | ART/DHA,  |   | The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer |
- | Review, | NA, | NA |
1026- | ART/DHA,  |   | Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma |
556- | ART/DHA,  |   | Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
- | Review, | NA, | NA |
558- | ART/DHA,  |   | Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer |
- | Review, | NA, | NA |
575- | ART/DHA,  |   | Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition |
- | in-vitro, | GBM, | U87MG |
571- | ART/DHA,  | TMZ,  |   | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
- | vitro+vivo, | GBM, | A172 | - | vitro+vivo, | GBM, | U87MG |
566- | ART/DHA,  | 2DG,  |   | Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
559- | ART/DHA,  |   | Artemisinin and its derivatives: a promising cancer therapy |
- | Review, | NA, | NA |
2323- | ART/DHA,  |   | Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 |
- | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 |
2570- | ART/DHA,  |   | Discovery, mechanisms of action and combination therapy of artemisinin |
- | Review, | Nor, | NA |
- | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT116 |
2580- | ART/DHA,  | VitC,  |   | Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells |
- | in-vitro, | AML, | NA |
2578- | ART/DHA,  | RES,  |   | Synergic effects of artemisinin and resveratrol in cancer cells |
- | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa |
2575- | ART/DHA,  | docx,  |   | Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC |
- | in-vitro, | Lung, | H23 |
3345- | ART/DHA,  |   | Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells |
- | in-vitro, | GBM, | NA |
3382- | ART/DHA,  |   | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
- | Review, | Var, | NA |
3383- | ART/DHA,  |   | Dihydroartemisinin: A Potential Natural Anticancer Drug |
- | Review, | Var, | NA |
3384- | ART/DHA,  |   | Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression |
- | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Liver, | HepG2 |
3391- | ART/DHA,  |   | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
- | Review, | Var, | NA |
3390- | ART/DHA,  |   | Ferroptosis: The Silver Lining of Cancer Therapy |
3389- | ART/DHA,  |   | Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers |
- | Review, | Var, | NA |
3387- | ART/DHA,  |   | Ferroptosis: A New Research Direction of Artemisinin and Its Derivatives in Anti-Cancer Treatment |
- | Review, | Var, | NA |
3396- | ART/DHA,  |   | Progress on the study of the anticancer effects of artesunate |
- | Review, | Var, | NA |
1370- | Ash,  |   | Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species |
- | in-vitro, | Lung, | A549 |
1367- | Ash,  |   | An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells |
- | in-vitro, | BC, | MDA-MB-231 |
1366- | Ash,  |   | Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling |
- | in-vitro, | BC, | MCF-7 |
1365- | Ash,  |   | Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells |
- | in-vitro, | Oral, | Ca9-22 | - | in-vitro, | Oral, | CAL27 |
1364- | Ash,  |   | Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress |
- | in-vitro, | Bladder, | J82 |
1363- | Ash,  | doxoR,  |   | Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer |
- | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | CaOV3 | - | in-vivo, | NA, | NA |
1362- | Ash,  | GEM,  |   | Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A |
- | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Hs766t |
- | in-vitro, | Liver, | HUH7 | - | in-vivo, | Liver, | HUH7 |
1360- | Ash,  | immuno,  |   | Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer |
- | in-vitro, | Lung, | H1650 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
1359- | Ash,  |   | Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231 |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
1358- | Ash,  |   | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
- | Review, | Var, | NA |
1368- | Ash,  | Cisplatin,  |   | Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’ |
- | in-vitro, | Colon, | HT-29 | - | in-vitro, | BC, | MDA-MB-231 |
1369- | Ash,  |   | Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis |
- | in-vitro, | Melanoma, | U266 |
1357- | Ash,  |   | Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | GL26 |
1356- | Ash,  |   | Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells |
- | in-vitro, | CRC, | HCT116 |
1355- | Ash,  |   | Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HMEC |
1372- | Ash,  |   | Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential |
- | in-vitro, | OS, | U2OS |
- | in-vitro, | AML, | HL-60 |
2003- | Ash,  |   | Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | TIG-1 | - | in-vitro, | PC, | LNCaP |
1142- | Ash,  |   | Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer |
- | Review, | BC, | MCF-7 | - | NA, | BC, | MDA-MB-231 | - | NA, | Nor, | HMEC |
3155- | Ash,  |   | Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera |
- | Review, | Var, | NA |
3156- | Ash,  |   | Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug |
- | Review, | Var, | NA |
3160- | Ash,  |   | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
- | Review, | Var, | NA |
3167- | Ash,  |   | Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo |
- | in-vitro, | MM, | H226 |
3177- | Ash,  |   | Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy |
- | Review, | Var, | NA |
3176- | Ash,  |   | Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex |
- | in-vitro, | NA, | NA |
3166- | Ash,  |   | Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives |
- | Review, | Var, | NA |
3172- | Ash,  |   | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
- | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
1900- | Aur,  |   | Potential Anticancer Activity of Auranofin |
- | Review, | Var, | NA |
874- | B-Gluc,  |   | Potential promising anticancer applications of β-glucans: a review |
- | Review, | NA, | NA |
- | in-vivo, | BC, | 4T1 |
2295- | Ba,  | 5-FU,  |   | Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway |
- | in-vitro, | GC, | AGS |
2296- | Ba,  |   | The most recent progress of baicalein in its anti-neoplastic effects and mechanisms |
- | Review, | Var, | NA |
2606- | Ba,  |   | Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma |
- | Review, | HCC, | NA |
2626- | Ba,  |   | Molecular targets and therapeutic potential of baicalein: a review |
- | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
2617- | Ba,  |   | Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review |
- | Review, | Var, | NA |
2615- | Ba,  |   | The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways |
- | Review, | Var, | NA |
2474- | Ba,  |   | Anticancer properties of baicalein: a review |
- | Review, | Var, | NA | - | in-vitro, | Nor, | BV2 |
2479- | Ba,  |   | Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells |
- | in-vitro, | HCC, | SW480 | - | in-vitro, | Pca, | PC3 |
2476- | Ba,  |   | Baicalein Induces Caspase-dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells |
- | in-vitro, | Lung, | A549 |
- | in-vitro, | BrCC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
1519- | Ba,  |   | ROS">Baicalein inhibits KB oral cancer cells by inducing apoptosis via modulation of ROS |
- | in-vitro, | Oral, | KB |
- | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | TOV-21G |
1523- | Ba,  |   | ROS-induced_BNIP3_expression">Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression |
- | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
- | in-vitro, | Lung, | A549 |
- | in-vitro, | Lung, | H1975 | - | in-vivo, | Lung, | NA |
1528- | Ba,  |   | Inhibiting reactive oxygen species-dependent autophagy enhanced baicalein-induced apoptosis in oral squamous cell carcinoma |
- | in-vitro, | OS, | CAL27 |
1529- | Ba,  |   | Studies on the Inhibitory Mechanisms of Baicalein in B16F10 Melanoma Cell Proliferation |
- | in-vitro, | Melanoma, | B16-F10 |
1532- | Ba,  |   | Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives |
- | Review, | NA, | NA |
1526- | Ba,  |   | Baicalein induces apoptosis through ROS-mediated mitochondrial dysfunction pathway in HL-60 cells |
- | in-vitro, | AML, | HL-60 |
2047- | BA,  |   | Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells |
- | in-vitro, | CRC, | T24 | - | in-vitro, | Nor, | SV-HUC-1 | - | in-vitro, | Bladder, | 5637 | - | in-vivo, | NA, | NA |
1299- | BBR,  |   | Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review |
- | Review, | NA, | NA |
2023- | BBR,  |   | Berberine Induces Caspase-Independent Cell Death in Colon Tumor Cells through Activation of Apoptosis-Inducing Factor |
- | in-vitro, | Colon, | NA | - | in-vitro, | Nor, | YAMC |
2021- | BBR,  |   | Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways |
- | Review, | NA, | NA |
1390- | BBR,  | Rad,  |   | Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells |
- | in-vitro, | Pca, | PC3 |
1398- | BBR,  |   | Berberine inhibits the progression of renal cell carcinoma cells by regulating reactive oxygen species generation and inducing DNA damage |
- | in-vitro, | Kidney, | NA |
1392- | BBR,  |   | Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress |
- | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
1393- | BBR,  | EPI,  |   | Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest |
- | in-vitro, | Bladder, | T24 |
1394- | BBR,  | DL,  |   | Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803 |
- | in-vitro, | GC, | MGC803 |
1395- | BBR,  |   | Analysis of the mechanism of berberine against stomach carcinoma based on network pharmacology and experimental validation |
- | in-vitro, | GC, | NA |
1396- | BBR,  |   | Berberine induced down-regulation of matrix metalloproteinase-1, -2 and -9 in human gastric cancer cells (SNU-5) in vitro |
- | in-vitro, | GC, | SNU1041 | - | in-vitro, | GC, | SNU5 |
1397- | BBR,  | Chemo,  |   | Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells |
- | in-vitro, | Lung, | A549 |
1399- | BBR,  | Rad,  |   | Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review |
- | Review, | NA, | NA |
1400- | BBR,  |   | Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells |
- | in-vitro, | Melanoma, | U266 |
1401- | BBR,  |   | Berberine induces apoptosis in glioblastoma multiforme U87MG cells via oxidative stress and independent of AMPK activity |
- | in-vitro, | GBM, | U87MG |
1402- | BBR,  |   | Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction |
- | in-vitro, | GBM, | T98G |
1404- | BBR,  |   | Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation |
- | in-vitro, | Pca, | PC3 |
1405- | BBR,  | Chit,  |   | Chitosan/alginate nanogel potentiate berberine uptake and enhance oxidative stress mediated apoptotic cell death in HepG2 cells |
- | in-vitro, | Liver, | HepG2 |
1374- | BBR,  | PDT,  |   | Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells |
- | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | HK-2 |
1387- | BBR,  |   | Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic Thyroid Carcinoma Cell Lines |
- | in-vitro, | Thyroid, | CAL-62 |
1386- | BBR,  |   | Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
1385- | BBR,  | 5-FU,  |   | Low-Dose Berberine Attenuates the Anti-Breast Cancer Activity of Chemotherapeutic Agents via Induction of Autophagy and Antioxidation |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
1384- | BBR,  |   | Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines |
- | in-vitro, | PC, | PANC1 |
1382- | BBR,  |   | Berberine increases the expression of cytokines and proteins linked to apoptosis in human melanoma cells |
- | in-vitro, | Melanoma, | SK-MEL-28 |
1381- | BBR,  | Rad,  |   | Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3) |
- | in-vitro, | Ovarian, | SKOV3 |
1389- | BBR,  | Lap,  |   | Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS |
- | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | AU-565 |
1379- | BBR,  |   | Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cells |
- | in-vitro, | lymphoma, | NA |
1375- | BBR,  |   | 13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein |
- | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
1376- | BBR,  | immuno,  |   | Berberine sensitizes immune checkpoint blockade therapy in melanoma by NQO1 inhibition and ROS activation |
- | in-vivo, | Melanoma, | NA |
2699- | BBR,  |   | Plant Isoquinoline Alkaloid Berberine Exhibits Chromatin Remodeling by Modulation of Histone Deacetylase To Induce Growth Arrest and Apoptosis in the A549 Cell Line |
- | in-vitro, | Lung, | A549 |
2674- | BBR,  |   | Berberine: A novel therapeutic strategy for cancer |
- | Review, | Var, | NA | - | Review, | IBD, | NA |
2680- | BBR,  | PDT,  |   | Photodynamic therapy-triggered nuclear translocation of berberine from mitochondria leads to liver cancer cell death |
- | in-vitro, | Liver, | HUH7 |
2681- | BBR,  | PDT,  |   | Berberine-photodynamic induced apoptosis by activating endoplasmic reticulum stress-autophagy pathway involving CHOP in human malignant melanoma cells |
- | in-vitro, | Melanoma, | NA |
2686- | BBR,  |   | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
- | Review, | Nor, | NA |
1473- | BCA,  | SFN,  |   | An Insight on Synergistic Anti-cancer Efficacy of Biochanin A and Sulforaphane Combination Against Breast Cancer |
- | in-vitro, | BC, | MCF-7 |
2753- | BetA,  |   | Betulinic acid induces apoptosis by regulating PI3K/Akt signaling and mitochondrial pathways in human cervical cancer cells |
- | in-vitro, | Cerv, | HeLa |
2752- | BetA,  |   | Betulinic acid: a natural product with anticancer activity |
- | Review, | Var, | NA |
2747- | BetA,  |   | Betulinic acid, a natural compound with potent anticancer effects |
- | Review, | Var, | NA |
2746- | BetA,  |   | Betulinic acid induces apoptosis and inhibits metastasis of human colorectal cancer cells in vitro and in vivo |
- | in-vitro, | CRC, | HCT116 | - | in-vivo, | CRC, | NA |
2745- | BetA,  |   | Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors |
- | in-vitro, | CRC, | RKO | - | in-vitro, | CRC, | SW480 | - | in-vivo, | NA, | NA |
2744- | BetA,  |   | Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential |
- | Review, | Var, | NA |
2759- | BetA,  |   | Chemopreventive and Chemotherapeutic Potential of Betulin and Betulinic Acid: Mechanistic Insights From In Vitro, In Vivo and Clinical Studies |
- | Review, | Var, | NA |
2716- | BetA,  |   | Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment |
- | Review, | Var, | NA |
2717- | BetA,  |   | Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma |
- | in-vitro, | Melanoma, | U266 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | RPMI-8226 |
2718- | BetA,  |   | The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis |
- | in-vitro, | AML, | U937 |
2720- | BetA,  |   | Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo |
- | in-vitro, | Cerv, | HeLa |
2721- | BetA,  |   | Proteomic Investigation into Betulinic Acid-Induced Apoptosis of Human Cervical Cancer HeLa Cells |
- | in-vitro, | Cerv, | HeLa |
2722- | BetA,  |   | Betulinic Acid for Cancer Treatment and Prevention |
- | Review, | Var, | NA |
2723- | BetA,  |   | Betulinic acid and oleanolic acid modulate CD81 expression and induce apoptosis in triple-negative breast cancer cells through ROS generation |
- | in-vitro, | BC, | MDA-MB-231 |
2726- | BetA,  |   | Betulinic acid induces DNA damage and apoptosis in SiHa cells |
- | in-vitro, | Cerv, | SiHa |
2727- | BetA,  |   | Betulinic acid in the treatment of breast cancer: Application and mechanism progress |
- | Review, | BC, | NA |
2729- | BetA,  |   | Betulinic acid in the treatment of tumour diseases: Application and research progress |
- | Review, | Var, | NA |
2739- | BetA,  |   | Glycolytic Switch in Response to Betulinic Acid in Non-Cancer Cells |
- | in-vitro, | Nor, | HUVECs | - | in-vitro, | Nor, | MEF |
2738- | BetA,  |   | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
2737- | BetA,  |   | Multiple molecular targets in breast cancer therapy by betulinic acid |
- | Review, | Var, | NA |
- | Review, | Var, | NA |
2735- | BetA,  |   | Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications |
- | Review, | Var, | NA |
2734- | BetA,  |   | Betulinic Acid Modulates the Expression of HSPA and Activates Apoptosis in Two Cell Lines of Human Colorectal Cancer |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
2733- | BetA,  |   | Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling |
- | in-vitro, | Oral, | KB | - | in-vivo, | NA, | NA |
2730- | BetA,  |   | Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells |
- | in-vitro, | Bladder, | T24 |
1566- | betaCar,  | Lyco,  |   | Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells |
- | in-vitro, | Nor, | HS68 |
726- | Bor,  |   | Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open |
- | Review, | NA, | NA |
720- | Bor,  |   | High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line |
- | in-vitro, | Pca, | DU145 |
722- | Bor,  |   | Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms |
- | in-vitro, | Ovarian, | MDAH-2774 |
727- | Bor,  | RSL3,  | erastin,  |   | Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy |
- | in-vitro, | Liver, | HepG2 |
746- | Bor,  |   | Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope |
- | Review, | NA, | NA |
3522- | Bor,  |   | The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry |
- | Review, | Var, | NA |
2776- | Bos,  |   | Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities |
- | Review, | Var, | NA |
2775- | Bos,  |   | The journey of boswellic acids from synthesis to pharmacological activities |
- | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
- | in-vitro, | Pca, | DU145 |
1421- | Bos,  |   | Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes |
- | in-vitro, | AML, | HL-60 | - | in-vitro, | Nor, | NA |
1448- | Bos,  |   | A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells |
- | in-vitro, | AML, | HL-60 |
1447- | Bos,  |   | Boswellia carterii n-hexane extract suppresses breast cancer growth via induction of ferroptosis by downregulated GPX4 and upregulated transferrin |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | MCF10 |
2024- | Bos,  |   | Antiproliferative and cell cycle arrest potentials of 3-O-acetyl-11-keto-β-boswellic acid against MCF-7 cells in vitro |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
3032- | CA,  |   | Carnosic Acid Induces Apoptosis Through Reactive Oxygen Species-mediated Endoplasmic Reticulum Stress Induction in Human Renal Carcinoma Caki Cells |
- | in-vitro, | Kidney, | Caki-1 |
1650- | CA,  |   | Adjuvant Properties of Caffeic Acid in Cancer Treatment |
- | Review, | Var, | NA |
1651- | CA,  | PBG,  |   | Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer |
- | Review, | Var, | NA |
1652- | CA,  |   | Caffeic Acid and Diseases—Mechanisms of Action |
- | Review, | Var, | NA |
- | in-vitro, | Cerv, | SiHa |
1259- | CAP,  |   | Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells |
- | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H2009 |
2014- | CAP,  |   | Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells |
- | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | HPDE-6 | - | in-vivo, | PC, | AsPC-1 |
2018- | CAP,  | MF,  |   | Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma |
- | Review, | HCC, | NA |
2019- | CAP,  |   | Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer |
- | Review, | Var, | NA |
2012- | CAP,  |   | Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways |
- | NA, | OS, | MG63 |
2020- | CAP,  |   | Capsaicinoids and Their Effects on Cancer: The “Double-Edged Sword” Postulate from the Molecular Scale |
- | Review, | Var, | NA |
1517- | CAP,  |   | Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1) |
- | in-vitro, | Bladder, | TSGH8301 | - | in-vitro, | CRC, | T24 |
2652- | CAP,  |   | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
- | Review, | Var, | NA |
939- | Catechins,  | 5-FU,  |   | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil |
- | vitro+vivo, | GC, | SNU620 |
603- | Catechins,  |   | Catechins induce oxidative damage to cellular and isolated DNA through the generation of reactive oxygen species |
- | in-vitro, | NA, | HL-60 |
2653- | Cela,  |   | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
- | Review, | Var, | NA |
1144- | CHr,  |   | 8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK |
- | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | Nor, | HL7702 |
2801- | CHr,  |   | AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells |
- | in-vitro, | Lung, | A549 |
2804- | CHr,  | Rad,  |   | Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway |
- | in-vitro, | CRC, | HT29 |
2781- | CHr,  | PBG,  |   | Chrysin a promising anticancer agent: recent perspectives |
- | Review, | Var, | NA |
2806- | CHr,  | Se,  |   | Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy |
- | in-vitro, | Var, | NA |
2792- | CHr,  |   | Chrysin induces death of prostate cancer cells by inducing ROS and ER stress |
- | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
2782- | CHr,  |   | Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives |
- | Review, | Var, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
2784- | CHr,  |   | Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review) |
- | Review, | Var, | NA |
2785- | CHr,  |   | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
- | Review, | Var, | NA |
2790- | CHr,  |   | Chrysin: Pharmacological and therapeutic properties |
- | Review, | Var, | NA |
2791- | CHr,  |   | Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction |
- | in-vitro, | Ovarian, | OV90 |
1249- | CHr,  |   | Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes |
- | in-vitro, | CLL, | NA |
1585- | Citrate,  |   | Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer |
- | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Nor, | HEK293 |
1593- | Citrate,  |   | Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma? |
- | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 |
2315- | Citrate,  |   | Why and how citrate may sensitize malignant tumors to immunotherapy |
- | Review, | Var, | NA |
1595- | Cu,  |   | The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy |
- | Review, | NA, | NA |
1596- | Cu,  | CDT,  |   | Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review |
- | Review, | NA, | NA |
1597- | Cu,  |   | Anticancer potency of copper(II) complexes of thiosemicarbazones |
- | Review, | NA, | NA |
1598- | Cu,  |   | Targeting copper in cancer therapy: 'Copper That Cancer' |
- | Review, | NA, | NA |
1599- | Cu,  |   | Copper in tumors and the use of copper-based compounds in cancer treatment |
- | Review, | NA, | NA |
1600- | Cu,  |   | Cu(II) complex that synergistically potentiates cytotoxicity and an antitumor immune response by targeting cellular redox homeostasis |
- | Review, | NA, | NA |
1601- | Cu,  |   | The copper (II) complex of salicylate phenanthroline induces immunogenic cell death of colorectal cancer cells through inducing endoplasmic reticulum stress |
- | in-vitro, | CRC, | NA |
1602- | Cu,  |   | A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy† |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
1603- | Cu,  | BP,  | SDT,  |   | Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response |
- | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
1604- | Cu,  |   | Targeting copper metabolism: a promising strategy for cancer treatment |
- | Review, | NA, | NA |
1572- | Cu,  |   | Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy |
- | Review, | NA, | NA |
1571- | Cu,  |   | Copper in cancer: From pathogenesis to therapy |
- | Review, | NA, | NA |
1570- | Cu,  |   | Development of copper nanoparticles and their prospective uses as antioxidants, antimicrobials, anticancer agents in the pharmaceutical sector |
- | Review, | NA, | NA |
1569- | Cu,  |   | Copper Nanoparticles as Therapeutic Anticancer Agents |
- | Review, | NA, | NA |
1639- | Cu,  | HCAs,  |   | Green synthesis of copper oxide nanoparticles using sinapic acid: an underpinning step towards antiangiogenic therapy for breast cancer |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
1609- | CUR,  | EA,  |   | Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells |
- | in-vitro, | Cerv, | NA |
1408- | CUR,  |   | Antiproliferative and ROS Regulation Activity of Photoluminescent Curcumin-Derived Nanodots |
- | in-vitro, | Lung, | A549 |
1410- | CUR,  |   | Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway |
- | vitro+vivo, | OS, | MG63 |
1409- | CUR,  |   | Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma |
- | in-vivo, | CCA, | Walker256 |
1383- | CUR,  | BBR,  | RES,  |   | Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases |
- | Review, | NA, | NA |
1978- | CUR,  |   | Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells |
- | in-vitro, | Cerv, | HeLa |
1979- | CUR,  | Rad,  |   | Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase |
- | in-vitro, | Lung, | A549 |
1980- | CUR,  | Rad,  |   | Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Laryn, | FaDu |
1981- | CUR,  |   | Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity |
- | in-vitro, | Lung, | NA |
2312- | CUR,  |   | Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy |
- | Review, | Var, | NA |
2308- | CUR,  |   | Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells |
- | in-vitro, | Liver, | HepG2 |
2688- | CUR,  |   | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
- | Review, | Var, | NA | - | Review, | AD, | NA |
2980- | CUR,  |   | Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation |
- | in-vivo, | PC, | NA |
2978- | CUR,  |   | N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells |
- | in-vitro, | Lung, | A549 |
2821- | CUR,  |   | Antioxidant curcumin induces oxidative stress to kill tumor cells (Review) |
- | Review, | Var, | NA |
2654- | CUR,  |   | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
- | Review, | Var, | NA |
872- | CUR,  | RES,  |   | New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects |
- | in-vitro, | BC, | TUBO | - | in-vitro, | BC, | SALTO |
143- | CUR,  |   | Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
134- | CUR,  | RES,  | MEL,  | SIL,  |   | Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
132- | CUR,  |   | Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells |
- | in-vitro, | Pca, | NA |
159- | CUR,  |   | Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment |
- | in-vitro, | Pca, | DU145 |
117- | CUR,  |   | Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells |
- | in-vivo, | Pca, | RM-1 | - | in-vivo, | Pca, | DU145 |
118- | CUR,  |   | Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
424- | CUR,  |   | Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
426- | CUR,  |   | Use of cancer chemopreventive phytochemicals as antineoplastic agents |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 |
414- | CUR,  |   | Transcriptome Investigation and In Vitro Verification of Curcumin-Induced HO-1 as a Feature of Ferroptosis in Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
412- | CUR,  |   | Curcumin and Its New Derivatives: Correlation between Cytotoxicity against Breast Cancer Cell Lines, Degradation of PTP1B Phosphatase and ROS Generation |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
410- | CUR,  |   | Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS |
- | vitro+vivo, | GC, | AGS | - | vitro+vivo, | GC, | HGC27 |
407- | CUR,  |   | Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress |
- | in-vitro, | Melanoma, | A375 |
405- | CUR,  | 5-FU,  |   | Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis |
- | vitro+vivo, | CRC, | HCT116 |
477- | CUR,  |   | Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells |
- | in-vitro, | Cerv, | SiHa |
462- | CUR,  |   | Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress |
- | in-vitro, | Pca, | PC3 |
448- | CUR,  |   | Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation |
- | in-vitro, | CRC, | HT-29 |
440- | CUR,  |   | Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells |
- | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HT-29 |
454- | CUR,  |   | Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway |
- | in-vitro, | GC, | MGC803 |
1885- | DCA,  |   | Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
1875- | DCA,  |   | Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells |
- | in-vitro, | neuroblastoma, | NA | - | in-vivo, | NA, | NA |
1873- | DCA,  |   | Dual-targeting of aberrant glucose metabolism in glioblastoma |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
1872- | DCA,  |   | Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment |
- | in-vitro, | Oral, | HSC2 | - | in-vitro, | Oral, | HSC3 |
1864- | DCA,  | MET,  |   | Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
1869- | DCA,  |   | Dichloroacetate induces autophagy in colorectal cancer cells and tumours |
- | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HT-29 |
1854- | dietFMD,  |   | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
- | Review, | Var, | NA |
1852- | dietFMD,  | Chemo,  |   | Starvation Based Differential Chemotherapy: A Novel Approach for Cancer Treatment |
- | Review, | Var, | NA |
1851- | dietFMD,  | Chemo,  |   | Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy |
- | in-vitro, | GBM, | LN229 | - | in-vitro, | neuroblastoma, | SH-SY5Y |
1847- | dietFMD,  | VitC,  |   | Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers |
- | in-vitro, | PC, | PANC1 |
1846- | dietFMD,  | VitC,  |   | A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer |
- | Study, | Var, | NA |
1844- | dietFMD,  |   | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
- | Review, | NA, | NA |
1860- | dietFMD,  | Chemo,  |   | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
- | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
1861- | dietFMD,  | Chemo,  |   | Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models |
- | in-vitro, | Colon, | CT26 | - | in-vivo, | NA, | NA |
1863- | dietFMD,  | Chemo,  |   | Effect of fasting on cancer: A narrative review of scientific evidence |
- | Review, | Var, | NA |
1810- | dietKeto,  | Oxy,  |   | The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer |
- | in-vivo, | Var, | NA |
2264- | dietMet,  |   | Methionine restriction for cancer therapy: From preclinical studies to clinical trials |
- | Review, | Var, | NA |
2267- | dietMet,  |   | Role of amino acids in regulation of ROS balance in cancer |
- | Review, | Var, | NA |
2272- | dietMet,  |   | Methionine restriction - Association with redox homeostasis and implications on aging and diseases |
- | Review, | Nor, | NA |
2273- | dietMet,  |   | Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
2155- | dietP,  |   | Transepithelial Anti-Neuroblastoma Response to Kale among Four Vegetable Juices Using In Vitro Model Co-Culture System |
- | in-vivo, | neuroblastoma, | Caco-2 | - | NA, | NA, | SH-SY5Y |
1606- | EA,  |   | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
- | in-vitro, | Colon, | HCT15 |
1608- | EA,  |   | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
1610- | EA,  |   | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
- | Review, | Cerv, | NA |
1611- | EA,  |   | Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues |
- | in-vitro, | Mal, | NA |
1613- | EA,  |   | Ellagitannins in Cancer Chemoprevention and Therapy |
- | Review, | Var, | NA |
1605- | EA,  |   | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
- | Review, | Var, | NA |
1620- | EA,  | Rad,  |   | Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: an in vitro study |
- | in-vitro, | Liver, | HepG2 |
1621- | EA,  |   | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
- | Review, | Var, | NA |
20- | EGCG,  |   | Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer |
- | in-vivo, | Liver, | NA | - | in-vivo, | Tong, | NA |
651- | EGCG,  |   | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications |
663- | EGCG,  |   | EGCG-coated silver nanoparticles self-assemble with selenium nanowires for treatment of drug-resistant bacterial infections by generating ROS and disrupting biofilms |
- | in-vitro, | NA, | NA |
642- | EGCG,  |   | Prooxidant Effects of Epigallocatechin-3-Gallate in Health Benefits and Potential Adverse Effect |
641- | EGCG,  | Se,  |   | Antioxidant effects of green tea |
695- | EGCG,  | TFdiG,  |   | The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention |
- | in-vitro, | NA, | HL-60 |
694- | EGCG,  |   | Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways |
- | in-vitro, | BC, | MCF-7 |
692- | EGCG,  |   | EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement |
- | Review, | NA, | NA |
676- | EGCG,  | Chemo,  |   | The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review |
- | Review, | NA, | NA |
668- | EGCG,  |   | The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment |
- | Review, | BC, | MCF-7 | - | Review, | BC, | MDA-MB-231 |
1303- | EGCG,  |   | (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation |
- | in-vitro, | EC, | NA |
- | in-vitro, | GBM, | U87MG |
1975- | EGCG,  |   | Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate |
- | in-vitro, | Cerv, | HeLa |
2309- | EGCG,  | Chemo,  |   | Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts |
- | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HPNE | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
2310- | EGCG,  |   | Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells |
- | in-vitro, | lymphoma, | PEL |
2563- | EGCG,  |   | Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies |
- | Review, | NA, | NA |
3205- | EGCG,  |   | The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas |
- | Review, | Var, | NA | - | Review, | AD, | NA |
3203- | EGCG,  |   | (-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress |
- | NA, | MM, | NA |
3238- | EGCG,  |   | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
- | Review, | Var, | NA |
3214- | EGCG,  |   | EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway |
- | in-vitro, | Nor, | MRC-5 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
3215- | EGCG,  |   | Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer |
- | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
3219- | EGCG,  |   | Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling |
- | in-vitro, | Lung, | A549 |
3223- | EGCG,  |   | The Effects of Green Tea Catechins in Hematological Malignancies |
- | Review, | AML, | NA |
988- | EMD,  |   | Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS |
- | in-vitro, | RCC, | NA |
1318- | EMD,  |   | Aloe-emodin Induces Apoptosis in Human Liver HL-7702 Cells through Fas Death Pathway and the Mitochondrial Pathway by Generating Reactive Oxygen Species |
- | in-vitro, | Nor, | HL7702 |
1321- | EMD,  |   | Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: roles of apoptotic cell death and LS1034 tumor xenografts model |
- | in-vitro, | CRC, | LS1034 | - | in-vivo, | NA, | NA |
1322- | EMD,  |   | The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers |
- | Review, | Var, | NA |
1323- | EMD,  |   | Anticancer action of naturally occurring emodin for the controlling of cervical cancer |
- | Review, | Cerv, | NA |
1245- | EMD,  |   | Emodin Exhibits Strong Cytotoxic Effect in Cervical Cancer Cells by Activating Intrinsic Pathway of Apoptosis |
- | in-vitro, | Cerv, | HeLa |
1324- | EMD,  |   | Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin |
- | Review, | Var, | NA |
1326- | EMD,  |   | Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells |
- | in-vitro, | Lung, | A549 |
1327- | EMD,  |   | Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway |
- | in-vitro, | Lung, | A549 |
1328- | EMD,  |   | Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways |
- | in-vitro, | Tong, | SCC4 |
1332- | EMD,  |   | Induction of Apoptosis in HepaRG Cell Line by Aloe-Emodin through Generation of Reactive Oxygen Species and the Mitochondrial Pathway |
- | in-vivo, | Nor, | HepaRG |
1331- | EMD,  |   | Aloe-emodin induces apoptosis of human nasopharyngeal carcinoma cells via caspase-8-mediated activation of the mitochondrial death pathway |
- | in-vitro, | NPC, | NA |
2455- | erastin,  |   | Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments |
- | in-vitro, | Cerv, | HeLa |
2204- | erastin,  |   | Regulation of ferroptotic cancer cell death by GPX4 |
- | in-vitro, | fibroS, | HT1080 |
1656- | FA,  |   | Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling |
- | Review, | Var, | NA |
1654- | FA,  |   | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
- | Review, | Var, | NA |
2496- | Fenb,  |   | Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells |
- | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
2494- | Fenb,  |   | Oral Fenbendazole for Cancer Therapy in Humans and Animals |
- | Review, | Var, | NA |
2844- | FIS,  |   | Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells |
- | in-vitro, | OS, | U2OS |
2845- | FIS,  |   | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
- | Review, | Var, | NA |
2847- | FIS,  |   | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
- | in-vitro, | CCA, | NA |
2849- | FIS,  |   | Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells |
- | in-vitro, | Melanoma, | U266 |
2852- | FIS,  |   | A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms |
- | Review, | CRC, | NA |
2853- | FIS,  |   | Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells |
- | in-vitro, | Thyroid, | TPC-1 |
2855- | FIS,  |   | Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells |
- | in-vitro, | RCC, | Caki-1 |
2856- | FIS,  |   | N -acetyl- L -cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells |
- | in-vitro, | Colon, | COLO205 |
2857- | FIS,  |   | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
- | Review, | Var, | NA |
2842- | FIS,  |   | Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells |
- | in-vitro, | GC, | AGS |
2824- | FIS,  |   | Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics |
- | Review, | Var, | NA |
2825- | FIS,  |   | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
- | Review, | Var, | NA |
2827- | FIS,  |   | The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment |
- | Review, | Var, | NA |
2828- | FIS,  |   | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
- | Review, | Var, | NA |
2829- | FIS,  |   | Fisetin: An anticancer perspective |
- | Review, | Var, | NA |
2830- | FIS,  |   | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
- | Review, | Var, | NA |
2832- | FIS,  |   | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
- | Review, | Var, | NA |
2833- | FIS,  | SNP,  |   | Glucose-capped fisetin silver nanoparticles induced cytotoxicity and ferroptosis in breast cancer cells: A molecular perspective |
- | in-vitro, | BC, | MDA-MB-231 |
2838- | FIS,  |   | Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down-regulating nuclear factor erythroid 2-related factor 2 (Nrf2) |
2839- | FIS,  |   | Dietary flavonoid fisetin for cancer prevention and treatment |
- | Review, | Var, | NA |
2840- | FIS,  |   | Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells |
- | NA, | CCA, | NA |
2843- | FIS,  |   | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
- | Review, | Var, | NA |
1624- | GA,  |   | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
- | in-vitro, | Cerv, | NA |
935- | Gallo,  |   | Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
- | in-vitro, | Lung, | A549 |
1973- | GamB,  |   | Gambogic acid deactivates cytosolic and mitochondrial thioredoxins by covalent binding to the functional domain |
- | in-vitro, | Liver, | SMMC-7721 cell |
1972- | GamB,  | doxoR,  |   | Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression |
- | in-vitro, | BC, | NA |
1970- | GamB,  |   | Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway |
- | NA, | Lung, | NCI-H441 |
1969- | GamB,  |   | Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
1967- | GamB,  |   | Gambogic acid induces apoptotic cell death in T98G glioma cells |
- | in-vitro, | GBM, | T98G |
2060- | GamB,  |   | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
- | in-vitro, | Pca, | NA |
1954- | GamB,  |   | Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase |
- | in-vitro, | HCC, | SMMC-7721 cell |
1955- | GamB,  |   | Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer |
- | in-vitro, | Pca, | NA |
1956- | GamB,  |   | Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis |
- | in-vitro, | Melanoma, | A375 |
1957- | GamB,  |   | Nanoscale Features of Gambogic Acid Induced ROS-Dependent Apoptosis in Esophageal Cancer Cells Imaged by Atomic Force Microscopy |
- | in-vitro, | ESCC, | EC9706 |
1958- | GamB,  |   | Gambogenic acid induces apoptosis and autophagy through ROS-mediated endoplasmic reticulum stress via JNK pathway in prostate cancer cells |
- | in-vitro, | Pca, | NA | - | in-vivo, | NA, | NA |
1961- | GamB,  |   | Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS |
- | in-vitro, | Melanoma, | RPMI-8226 |
1962- | GamB,  | HCQ,  |   | Gambogic acid induces autophagy and combines synergistically with chloroquine to suppress pancreatic cancer by increasing the accumulation of reactive oxygen species |
- | in-vitro, | PC, | NA |
1963- | GamB,  |   | Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model |
- | in-vitro, | Lung, | NA |
1965- | GamB,  | doxoR,  |   | Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis |
- | in-vitro, | Ovarian, | SKOV3 |
1966- | GamB,  | Cisplatin,  |   | Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | NCIH1299 |
1960- | GamB,  | Vem,  |   | Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation |
- | in-vitro, | Liver, | HepG2 | - | in-vitro, | AML, | K562 |
823- | GAR,  |   | Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 | - | in-vitro, | CRC, | HCT116 |
822- | GAR,  |   | Garcinol, a Polyisoprenylated Benzophenone Modulates Multiple Proinflammatory Signaling Cascades Leading to the Suppression of Growth and Survival of Head and Neck Carcinoma |
- | vitro+vivo, | HNSCC, | NA |
821- | GAR,  |   | Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis |
- | in-vitro, | Liver, | Hep3B |
820- | GAR,  |   | Garcinol in gastrointestinal cancer prevention: recent advances and future prospects |
- | Review, | NA, | NA |
805- | GAR,  | Cisplatin,  | PacT,  |   | Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells |
- | Review, | NA, | NA |
1407- | GoldNP,  | Z,  |   | The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition |
- | in-vivo, | NA, | NA |
1901- | GoldNP,  | Rad,  |   | The role of thioredoxin reductase in gold nanoparticle radiosensitization effects |
- | in-vitro, | Lung, | A549 |
1904- | GoldNP,  | SNP,  |   | Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis |
- | in-vitro, | Lung, | H157 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Melanoma, | A375 |
3526- | GoldNP,  | Rad,  |   | Advances in nanoparticle-based radiotherapy for cancer treatment |
- | Review, | Var, | NA |
848- | Gra,  | SNP,  |   | Synthesis, Characterization and Evaluation of Antioxidant and Cytotoxic Potential of Annona muricata Root Extract-derived Biogenic Silver Nanoparticles |
- | in-vitro, | CRC, | HCT116 |
845- | Gra,  |   | A Review on Annona muricata and Its Anticancer Activity |
- | Review, | NA, | NA |
844- | Gra,  |   | Annona muricata Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
835- | Gra,  |   | Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB |
- | in-vitro, | Lung, | A549 |
834- | Gra,  |   | Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review |
- | Review, | NA, | NA |
856- | Gra,  |   | https://pubmed.ncbi.nlm.nih.gov/33048613/ |
- | in-vitro, | BC, | MCF-7 |
858- | Gra,  |   | Annona muricata leaves induce G₁ cell cycle arrest and apoptosis through mitochondria-mediated pathway in human HCT-116 and HT-29 colon cancer cells |
- | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 |
1232- | Gra,  |   | Graviola: A Systematic Review on Its Anticancer Properties |
- | Review, | NA, | NA |
2508- | H2,  |   | Molecular hydrogen is a promising therapeutic agent for pulmonary disease |
- | Review, | Var, | NA | - | Review, | Sepsis, | NA |
2522- | H2,  |   | A Systematic Review of Molecular Hydrogen Therapy in Cancer Management |
- | Review, | Var, | NA |
2519- | H2,  |   | Hydrogen: an advanced and safest gas option for cancer treatment |
- | Review, | Var, | NA |
2509- | H2,  |   | Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway |
- | in-vitro, | Endo, | AN3CA | - | in-vivo, | Endo, | NA |
2511- | H2,  |   | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
- | in-vivo, | GBM, | U87MG |
2516- | H2,  |   | Hydrogen Gas in Cancer Treatment |
- | Review, | Var, | NA |
2528- | H2,  |   | Local generation of hydrogen for enhanced photothermal therapy |
- | in-vitro, | Var, | NA |
1628- | HCA,  | ALA,  |   | Addition of Hydroxy Citrate improves effect of ALA |
- | Review, | Var, | NA |
602- | HCAs,  |   | Prooxidant activity of hydroxycinnamic acids on DNA damage in the presence of Cu(II) ions: mechanism and structure-activity relationship |
- | Analysis, | NA, | NA |
1641- | HCAs,  |   | Lung cancer induced by Benzo(A)Pyrene: ChemoProtective effect of sinapic acid in swiss albino mice |
- | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA |
1638- | HCAs,  |   | Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications |
- | Review, | Nor, | NA |
1643- | HCAs,  |   | Mechanisms involved in the anticancer effects of sinapic acid |
- | Review, | Var, | NA |
1004- | HNK,  | RAPA,  |   | Honokiol downregulates PD-L1 expression and enhances antitumor effects of mTOR inhibitors in renal cancer cells |
- | in-vitro, | RCC, | NA |
2079- | HNK,  |   | Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway |
- | in-vitro, | Nor, | PC12 |
2081- | HNK,  |   | Honokiol induces ferroptosis in colon cancer cells by regulating GPX4 activity |
- | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | LS174T | - | in-vitro, | Colon, | HCT8 | - | in-vitro, | Colon, | SW480 | - | in-vivo, | NA, | NA |
2073- | HNK,  |   | Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo |
- | in-vitro, | OS, | U2OS | - | in-vivo, | NA, | NA |
2072- | HNK,  |   | Honokiol Suppresses Cell Proliferation and Tumor Migration through ROS in Human Anaplastic Thyroid Cancer Cells |
- | in-vitro, | Thyroid, | NA |
2883- | HNK,  |   | Honokiol targets mitochondria to halt cancer progression and metastasis |
- | Review, | Var, | NA |
2889- | HNK,  | doxoR,  |   | Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice |
- | in-vivo, | Nor, | NA |
2895- | HNK,  |   | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
- | in-vitro, | Lung, | PC9 |
2891- | HNK,  |   | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
- | Review, | Var, | NA |
2879- | HNK,  |   | Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function |
- | in-vitro, | Lung, | H226 | - | in-vivo, | NA, | NA |
2863- | HNK,  |   | Honokiol induces paraptosis-like cell death through mitochondrial ROS-dependent endoplasmic reticulum stress in hepatocellular carcinoma Hep3B cells |
- | in-vitro, | Liver, | Hep3B |
2864- | HNK,  |   | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
- | Review, | Var, | NA |
2865- | HNK,  |   | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
- | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
886- | HPT,  |   | Impact of hyper- and hypothermia on cellular and whole-body physiology |
- | Analysis, | NA, | NA |
1175- | IVM,  | PDT,  |   | Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors |
- | in-vitro, | Var, | NA |
1918- | JG,  |   | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
- | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
1927- | JG,  |   | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
- | in-vitro, | GC, | SGC-7901 |
1926- | JG,  |   | Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway |
- | in-vitro, | BC, | MCF-7 |
1925- | JG,  |   | Redox regulation of mitochondrial functional activity by quinones |
- | in-vitro, | NA, | NA |
1917- | JG,  |   | Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion |
- | in-vitro, | AML, | HL-60 |
1919- | JG,  |   | The Anti-Glioma Effect of Juglone Derivatives through ROS Generation |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
1920- | JG,  | TQ,  | Plum,  |   | Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line |
- | in-vitro, | PC, | PANC1 |
1921- | JG,  |   | Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis |
- | in-vitro, | PC, | NA | - | vitro+vivo, | PC, | NA |
1922- | JG,  |   | Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma |
- | in-vitro, | GBM, | U87MG |
1923- | JG,  |   | Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells |
- | in-vitro, | Endo, | NA |
1924- | JG,  |   | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
- | in-vitro, | Lung, | A549 |
2351- | lamb,  |   | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
- | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
1100- | LT,  |   | Luteolin, a flavonoid, as an anticancer agent: A review |
- | Review, | NA, | NA |
2916- | LT,  |   | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
- | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
2917- | LT,  | Rad,  |   | Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade |
- | in-vitro, | Lung, | NA |
2918- | LT,  |   | Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS |
- | in-vitro, | Melanoma, | A375 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | SK-MEL-28 |
2919- | LT,  |   | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
- | Review, | Var, | NA |
2921- | LT,  |   | Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies |
- | Review, | Nor, | NA |
2922- | LT,  |   | Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC |
- | in-vitro, | Liver, | HUH7 |
2913- | LT,  |   | Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells |
- | in-vitro, | GC, | HGC27 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | GC, | MKN45 |
2914- | LT,  |   | Therapeutic Potential of Luteolin on Cancer |
- | Review, | Var, | NA |
2903- | LT,  |   | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
- | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
2906- | LT,  |   | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
- | Review, | Var, | NA |
2912- | LT,  |   | Luteolin: a flavonoid with a multifaceted anticancer potential |
- | Review, | Var, | NA |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Liver, | HepG2 |
1720- | Lyco,  |   | Antioxidant and Pro-oxidant Activities of Carotenoids |
- | Review, | Nor, | NA |
1718- | Lyco,  |   | The role of carotenoids in the prevention of human pathologies |
- | Review, | Var, | NA |
1717- | Lyco,  |   | Potential Role of Carotenoids as Antioxidants in Human Health and Disease |
- | Review, | Var, | NA |
1716- | Lyco,  |   | Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species |
- | in-vitro, | AML, | RAW264.7 |
1715- | Lyco,  |   | Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence |
- | Review, | Var, | NA |
1712- | Lyco,  |   | Lycopene Protects against Smoking-Induced Lung Cancer by Inducing Base Excision Repair |
- | in-vitro, | Lung, | A549 |
1711- | Lyco,  |   | Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review |
- | Review, | Var, | NA |
1710- | Lyco,  |   | Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases |
- | Review, | CardioV, | NA |
2547- | M-Blu,  | SDT,  |   | The effect of dual-frequency ultrasound waves on B16F10 melanoma cells: Sonodynamic therapy using nanoliposomes containing methylene blue |
- | in-vitro, | Melanoma, | B16-BL6 |
2542- | M-Blu,  |   | In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death |
- | in-vitro, | Ovarian, | OV1369 | - | in-vitro, | Ovarian, | OV1946 | - | in-vitro, | Nor, | ARPE-19 |
2541- | M-Blu,  |   | Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism |
- | in-vivo, | Var, | NA |
2535- | M-Blu,  | SDT,  |   | Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action |
- | in-vitro, | Ovarian, | HO-8910 |
2534- | M-Blu,  | doxoR,  | PDT,  |   | Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells |
- | in-vitro, | CRC, | HT-29 |
2533- | M-Blu,  | PDT,  |   | Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells |
- | in-vitro, | Lung, | A549 |
1898- | MeJa,  |   | Methyl jasmonate and its potential in cancer therapy |
- | Review, | Var, | NA |
1899- | MeJa,  |   | Methyl jasmonate induces production of reactive oxygen species and alterations in mitochondrial dynamics that precede photosynthetic dysfunction and subsequent cell death |
- | in-vitro, | NA, | NA |
1779- | MEL,  |   | Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review |
- | Review, | BC, | NA |
1778- | MEL,  |   | Melatonin: a well-documented antioxidant with conditional pro-oxidant actions |
- | Review, | Var, | NA | - | Review, | AD, | NA |
1777- | MEL,  |   | Melatonin as an antioxidant: under promises but over delivers |
- | Review, | NA, | NA |
1776- | MEL,  |   | Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis |
- | Review, | NA, | NA |
995- | MEL,  |   | Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma |
- | vitro+vivo, | GBM, | NA |
1063- | MEL,  |   | HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
1204- | MET,  |   | Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
2247- | MF,  |   | Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis |
- | in-vivo, | Nor, | NA |
2245- | MF,  |   | Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis |
- | in-vitro, | Nor, | NIH-3T3 |
2244- | MF,  |   | Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer |
- | Review, | Var, | NA |
2241- | MF,  |   | Pulsed electromagnetic therapy in cancer treatment: Progress and outlook |
- | Review, | Var, | NA |
2260- | MF,  |   | Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 | - | in-vivo, | NA, | NA |
2261- | MF,  |   | Tumor-specific inhibition with magnetic field |
- | in-vitro, | Nor, | GP-293 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
2251- | MF,  | Rad,  |   | BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage |
- | in-vitro, | Lung, | A549 | - | in-vitro, | HNSCC, | UTSCC15 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | PC, | MIA PaCa-2 |
3500- | MF,  |   | Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress |
- | in-vitro, | Ovarian, | SKOV3 |
3486- | MF,  |   | Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death |
- | in-vitro, | NA, | NA |
3470- | MF,  |   | Pulsed electromagnetic fields inhibit IL-37 to alleviate CD8+ T cell dysfunction and suppress cervical cancer progression |
- | in-vitro, | Cerv, | HeLa |
3457- | MF,  |   | Cellular stress response to extremely low‐frequency electromagnetic fields (ELF‐EMF): An explanation for controversial effects of ELF‐EMF on apoptosis |
- | Review, | Var, | NA |
3468- | MF,  |   | An integrative review of pulsed electromagnetic field therapy (PEMF) and wound healing |
- | Review, | NA, | NA |
3469- | MF,  |   | Pulsed Electromagnetic Fields (PEMF)—Physiological Response and Its Potential in Trauma Treatment |
- | Review, | NA, | NA |
3480- | MF,  |   | Cellular and Molecular Effects of Magnetic Fields |
- | Review, | NA, | NA |
3477- | MF,  |   | Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis |
- | Review, | NA, | NA |
496- | MF,  |   | Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | ZR-75-1 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
500- | MF,  |   | Anti-Oxidative and Immune Regulatory Responses of THP-1 and PBMC to Pulsed EMF Are Field-Strength Dependent |
- | in-vitro, | AML, | THP1 |
503- | MF,  |   | Effects of acute and chronic low frequency electromagnetic field exposure on PC12 cells during neuronal differentiation |
- | in-vitro, | NA, | PC12 |
526- | MF,  |   | Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | HeLa | - | vitro+vivo, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | HEK293 |
490- | MF,  |   | Extremely Low Frequency Magnetic Field (ELF-MF) Exposure Sensitizes SH-SY5Y Cells to the Pro-Parkinson's Disease Toxin MPP(.) |
- | in-vitro, | Park, | SH-SY5Y |
582- | MF,  | immuno,  | VitC,  |   | Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy |
- | in-vitro, | Pca, | TRAMP-C1 | - | in-vivo, | NA, | NA |
587- | MF,  | VitC,  |   | Effect of stationary magnetic field strengths of 150 and 200 mT on reactive oxygen species production in soybean |
527- | MF,  |   | Effects of Fifty-Hertz Electromagnetic Fields on Granulocytic Differentiation of ATRA-Treated Acute Promyelocytic Leukemia NB4 Cells |
- | in-vitro, | AML, | APL NB4 |
538- | MF,  |   | The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Melanoma, | MSTO-211H |
537- | MF,  | immuno,  |   | Integrating electromagnetic cancer stress with immunotherapy: a therapeutic paradigm |
- | Review, | Var, | NA |
533- | MF,  |   | Effects of extremely low-frequency magnetic fields on human MDA-MB-231 breast cancer cells: proteomic characterization |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
532- | MF,  |   | A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
529- | MF,  |   | Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives |
- | Review, | GBM, | NA |
507- | MF,  |   | Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism |
- | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 |
508- | MF,  | doxoR,  |   | Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line |
- | in-vitro, | BC, | MCF-7 |
- | Review, | NA, | NA |
520- | MF,  |   | Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3β signaling pathway |
- | in-vitro, | Nor, | NA |
188- | MFrot,  |   | Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells |
- | in-vitro, | GBM, | GBM115 | - | in-vitro, | GBM, | DIPG |
187- | MFrot,  |   | Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice |
- | in-vivo, | GBM, | NA |
199- | MFrot,  |   | Modulation of Cellular Response to Different Parameters of the Rotating Magnetic Field (RMF)—An In Vitro Wound Healing Study |
- | in-vivo, | Wounds, | L929 | - | NA, | NA, | HaCaT |
220- | MFrot,  |   | Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation |
- | in-vitro, | Melanoma, | B16-F10 |
225- | MFrot,  |   | Extremely low frequency magnetic fields regulate differentiation of regulatory T cells: Potential role for ROS-mediated inhibition on AKT |
- | vitro+vivo, | Lung, | NA |
227- | MFrot,  |   | Low Frequency Magnetic Fields Induce Autophagy-associated Cell Death in Lung Cancer through miR-486-mediated Inhibition of Akt/mTOR Signaling Pathway |
- | in-vivo, | Lung, | A549 | - | in-vitro, | Lung, | A549 |
184- | MFrot,  |   | Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells |
- | in-vitro, | GBM, | GBM |
186- | MFrot,  |   | Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields |
- | in-vitro, | GBM, | GBM | - | in-vitro, | Lung, | NA |
516- | MFrot,  | immuno,  |   | Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth |
- | vitro+vivo, | GBM, | U87MG |
2258- | MFrot,  |   | EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE |
- | in-vitro, | GBM, | GBM | - | in-vitro, | Nor, | SVGp12 |
2259- | MFrot,  |   | Method and apparatus for oncomagnetic treatment |
- | in-vitro, | GBM, | NA |
773- | Mg,  |   | Methyl Jasmonate-induced Increase in Intracellular Magnesium Promotes Apoptosis in Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 |
1892- | MGO,  |   | Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights |
- | Review, | NA, | NA |
1891- | MGO,  |   | Methylglyoxal induces mitochondria-dependent apoptosis in sarcoma |
- | in-vitro, | SCC, | NA |
1998- | Myr,  | CUR,  |   | Thioredoxin-dependent system. Application of inhibitors |
- | Review, | Var, | NA |
1997- | Myr,  | QC,  |   | Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity |
- | in-vitro, | Lung, | A549 |
116- | Myrrh,  |   | The Role of Myrrh Metabolites in Cancer, Inflammation, and Wound Healing: Prospects for a Multi-Targeted Drug Therapy |
- | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | K562 | - | in-vitro, | BC, | KAIMRC1 |
1311- | NarG,  | Rad,  |   | Naringenin sensitizes lung cancer NCI-H23 cells to radiation by downregulation of akt expression and metastasis while promoting apoptosis |
- | in-vitro, | Lung, | H23 |
1807- | NarG,  |   | A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies |
- | Review, | NA, | NA |
1799- | NarG,  |   | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
- | Review, | NA, | NA |
1271- | NCL,  |   | Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics |
- | vitro+vivo, | Ovarian, | SKOV3 |
946- | Nimb,  |   | Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis |
- | in-vivo, | NA, | NA |
1814- | Oxy,  |   | Hyperbaric oxygen therapy for malignancy: a review |
- | Review, | Var, | NA |
1813- | Oxy,  |   | Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment |
- | Review, | Var, | NA |
2451- | PA,  |   | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
- | Review, | Var, | NA |
2452- | PA,  |   | Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis |
- | in-vitro, | BC, | SkBr3 |
1988- | Part,  |   | Parthenolide Induces ROS-Mediated Apoptosis in Lymphoid Malignancies |
- | in-vitro, | lymphoma, | NCI-H929 |
1996- | Part,  |   | Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells |
- | in-vitro, | CRC, | COLO205 |
1993- | Part,  |   | Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer |
- | in-vitro, | Cerv, | HeLa |
1992- | Part,  |   | Parthenolide induces ROS-dependent cell death in human gastric cancer cell |
- | in-vitro, | BC, | MGC803 |
1991- | Part,  |   | A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability |
- | in-vitro, | Liver, | HUH7 |
1989- | Part,  |   | Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties |
- | Review, | Var, | NA |
1987- | Part,  | Rad,  |   | A NADPH oxidase dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | PrEC |
1986- | Part,  |   | Modulation of Cell Surface Protein Free Thiols: A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide |
- | in-vitro, | NA, | NA |
1985- | Part,  |   | KEAP1 Is a Redox Sensitive Target That Arbitrates the Opposing Radiosensitive Effects of Parthenolide in Normal and Cancer Cells |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | PrEC | - | in-vivo, | NA, | NA |
1984- | Part,  |   | Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells |
- | in-vitro, | Cerv, | HeLa |
1983- | Part,  |   | Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells |
- | in-vitro, | Cerv, | HeLa |
2055- | PB,  |   | The Effects of Butyric Acid on the Differentiation, Proliferation, Apoptosis, and Autophagy of IPEC-J2 Cells |
- | in-vitro, | Nor, | IPEC-J2 |
2054- | PB,  |   | Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis |
- | in-vitro, | EC, | ISH | - | in-vitro, | EC, | HEC1B |
2039- | PB,  |   | TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
2069- | PB,  |   | Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes |
- | in-vitro, | Tong, | NA |
2065- | PB,  | TMZ,  |   | Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells |
- | in-vitro, | GBM, | NA |
2028- | PB,  |   | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
- | Review, | Var, | NA |
2077- | PB,  |   | Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells |
- | in-vitro, | Liver, | HUH7 |
1664- | PBG,  |   | Anticancer Activity of Propolis and Its Compounds |
- | Review, | Var, | NA |
1666- | PBG,  |   | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
- | Review, | Var, | NA |
1668- | PBG,  |   | Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms |
- | Review, | Var, | NA |
1672- | PBG,  |   | The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers |
- | Review, | BC, | NA |
1663- | PBG,  |   | Propolis and Their Active Constituents for Chronic Diseases |
- | Review, | Var, | NA |
1684- | PBG,  |   | Antitumor Activity of Chinese Propolis in Human Breast Cancer MCF-7 and MDA-MB-231 Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs |
1685- | PBG,  |   | Antitumor Activity of Chinese Propolis in Human Breast Cancer MCF-7 and MDA-MB-231 Cells |
- | in-vitro, | BC, | MCF-7 |
1673- | PBG,  |   | An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms |
- | Review, | Var, | NA |
1674- | PBG,  | SDT,  | HPT,  |   | Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells |
- | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | H6c7 |
1675- | PBG,  |   | Portuguese Propolis Antitumoral Activity in Melanoma Involves ROS Production and Induction of Apoptosis |
- | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | WM983B |
1676- | PBG,  |   | Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies |
- | Review, | Var, | NA |
2381- | PBG,  |   | Chinese Poplar Propolis Inhibits MDA-MB-231 Cell Proliferation in an Inflammatory Microenvironment by Targeting Enzymes of the Glycolytic Pathway |
- | in-vitro, | BC, | MDA-MB-231 |
2430- | PBG,  |   | The cytotoxic effects of propolis on breast cancer cells involve PI3K/Akt and ERK1/2 pathways, mitochondrial membrane potential, and reactive oxygen species generation |
- | in-vitro, | BC, | MDA-MB-231 |
1763- | PG,  |   | Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment |
- | Review, | NA, | NA |
1764- | PG,  | Cu,  |   | DNA strand break induction and enhanced cytotoxicity of propyl gallate in the presence of copper(II) |
- | in-vitro, | Nor, | GM05757 |
1767- | PG,  |   | Propyl gallate induces cell death in human pulmonary fibroblast through increasing reactive oxygen species levels and depleting glutathione |
- | in-vitro, | Nor, | NA |
1769- | PG,  |   | The Anti-Apoptotic Effects of Caspase Inhibitors in Propyl Gallate-Treated Lung Cancer Cells Are Related to Changes in Reactive Oxygen Species and Glutathione Levels |
- | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
1765- | PG,  |   | Enhanced cell death effects of MAP kinase inhibitors in propyl gallate-treated lung cancer cells are related to increased ROS levels and GSH depletion |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 |
1254- | PI,  | VitC,  |   | Piperlongumine combined with vitamin C as a new adjuvant therapy against gastric cancer regulates the ROS–STAT3 pathway |
- | in-vivo, | GC, | NA |
1256- | PI,  |   | Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models |
- | in-vitro, | adrenal, | PHEO | - | in-vivo, | NA, | NA |
2649- | PL,  |   | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
- | Review, | Var, | NA |
2966- | PL,  |   | A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles |
- | in-vitro, | LiverDam, | NA |
2968- | PL,  | Chit,  |   | Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy |
- | in-vitro, | GC, | AGS |
2969- | PL,  |   | Piperlongumine induces autophagy by targeting p38 signaling |
- | in-vitro, | OS, | U2OS | - | in-vitro, | Cerv, | HeLa |
2973- | PL,  |   | The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 |
2961- | PL,  |   | Piperlongumine inhibits esophageal squamous cell carcinoma in vitro and in vivo by triggering NRF2/ROS/TXNIP/NLRP3-dependent pyroptosis |
- | in-vitro, | ESCC, | KYSE-30 |
2958- | PL,  |   | Natural product piperlongumine inhibits proliferation of oral squamous carcinoma cells by inducing ferroptosis and inhibiting intracellular antioxidant capacity |
- | in-vitro, | Oral, | HSC3 |
2957- | PL,  |   | Piperlongumine Induces Cell Cycle Arrest via Reactive Oxygen Species Accumulation and IKKβ Suppression in Human Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 |
2956- | PL,  |   | Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis |
- | in-vitro, | PC, | NA |
2954- | PL,  |   | The metabolites from traditional Chinese medicine targeting ferroptosis for cancer therapy |
- | Review, | Var, | NA |
2953- | PL,  |   | Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation |
- | in-vitro, | Nor, | NA |
2952- | PL,  |   | Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization |
- | in-vitro, | Bladder, | T24 | - | in-vivo, | Bladder, | NA |
2950- | PL,  |   | Overview of piperlongumine analogues and their therapeutic potential |
- | Review, | Var, | NA |
2949- | PL,  |   | Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation |
- | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
2947- | PL,  |   | Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer |
- | Review, | Var, | NA |
2946- | PL,  |   | Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent |
- | Review, | Var, | NA |
2945- | PL,  |   | Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells |
- | in-vitro, | CRC, | HCT116 |
2944- | PL,  |   | Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells |
- | in-vitro, | Thyroid, | IHH4 | - | in-vitro, | Thyroid, | 8505C | - | in-vivo, | NA, | NA |
2943- | PL,  |   | Piperlongumine Inhibits Thioredoxin Reductase 1 by Targeting Selenocysteine Residues and Sensitizes Cancer Cells to Erastin |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF-7 |
2942- | PL,  |   | Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems |
- | in-vitro, | CRC, | CT26 | - | in-vitro, | CRC, | DLD1 | - | in-vivo, | CRC, | CT26 |
2941- | PL,  |   | Selective killing of cancer cells by a small molecule targeting the stress response to ROS |
- | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | OS, | U2OS | - | in-vitro, | BC, | MDA-MB-453 |
2940- | PL,  |   | Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors |
- | in-vitro, | PC, | PANC1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Kidney, | 786-O | - | in-vitro, | BC, | SkBr3 |
1950- | PL,  |   | Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 |
1938- | PL,  |   | Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation |
- | Study, | PSA, | NA | - | in-vivo, | NA, | NA |
1939- | PL,  |   | Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP |
- | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HUH7 | - | in-vivo, | NA, | NA |
1940- | PL,  |   | Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways |
- | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
1941- | PL,  |   | Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer |
- | in-vitro, | HNSCC, | NA |
1942- | PL,  |   | Piperlongumine inhibits antioxidant enzymes, increases ROS levels, induces DNA damage and G2/M cell cycle arrest in breast cell lines |
- | in-vitro, | BC, | MCF-7 |
1943- | PL,  |   | Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells |
- | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
1944- | PL,  |   | Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress |
- | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
1945- | PL,  | SANG,  |   | The Synergistic Effect of Piperlongumine and Sanguinarine on the Non-Small Lung Cancer |
- | in-vitro, | Lung, | A549 |
1946- | PL,  | PI,  |   | Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling |
- | in-vitro, | Liver, | NA |
1947- | PL,  |   | Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer |
- | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | NA |
1948- | PL,  | born,  |   | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
- | in-vitro, | GBM, | NA |
1949- | PL,  |   | Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | Cerv, | HeLa |
1951- | PL,  |   | Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation |
- | in-vitro, | Lung, | A549 |
1952- | PL,  | 5-FU,  |   | Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR |
- | in-vivo, | CRC, | HCT8 |
1953- | PL,  |   | Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | WI38 |
2004- | Plum,  |   | Plumbagin Inhibits Proliferative and Inflammatory Responses of T Cells Independent of ROS Generation But by Modulating Intracellular Thiols |
- | in-vivo, | Var, | NA |
2006- | Plum,  |   | Plumbagin induces apoptosis in human osteosarcoma through ROS generation, endoplasmic reticulum stress and mitochondrial apoptosis pathway |
- | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
2005- | Plum,  |   | Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2) |
- | in-vivo, | Nor, | EL4 | - | in-vitro, | AML, | Jurkat |
2651- | Plum,  |   | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
- | Review, | Var, | NA |
1237- | PS,  |   | Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade |
- | in-vitro, | Ovarian, | SKOV3 |
1201- | QC,  |   | Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1 |
- | in-vivo, | BC, | NA |
68- | QC,  | BaP,  |   | Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines |
- | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PrEC |
41- | QC,  |   | Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft |
- | vitro+vivo, | AML, | HL-60 |
39- | QC,  |   | A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells |
- | Analysis, | NA, | NA |
38- | QC,  |   | Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways |
- | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
36- | QC,  |   | Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
35- | QC,  |   | Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product |
88- | QC,  | PacT,  |   | Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production |
- | vitro+vivo, | Pca, | PC3 |
90- | QC,  | HP,  |   | Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA‑21 |
- | in-vitro, | Pca, | PC3 |
914- | QC,  |   | Quercetin and Cancer Chemoprevention |
- | Review, | NA, | NA |
915- | QC,  |   | Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management |
- | Review, | NA, | NA |
- | Analysis, | NA, | NA |
919- | QC,  |   | Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells |
- | in-vitro, | CRC, | HCT116 |
920- | QC,  |   | Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin |
- | Review, | NA, | NA |
921- | QC,  |   | Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin |
- | in-vitro, | lymphoma, | U937 |
922- | QC,  |   | Quercetin and ovarian cancer: An evaluation based on a systematic review |
- | Review, | NA, | NA |
923- | QC,  |   | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
- | Review, | Var, | NA |
910- | QC,  |   | The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism |
889- | QC,  |   | The multifaceted role of quercetin derived from its mitochondrial mechanism |
- | vitro+vivo, | Var, | NA |
890- | QC,  |   | PROOXIDANT ACTIVITIES OF ANTIOXIDANTS AND THEIR IMPACT ON HEALTH |
- | Review, | Var, | NA |
891- | QC,  |   | Chapter 9 - Quercetin: Prooxidant Effect and Apoptosis in Cancer |
- | in-vitro, | Var, | NA |
892- | QC,  |   | Antioxidant vs. pro-oxidant activities of quercetin in aqueous phase: A Density Functional Theory study |
- | Analysis, | Var, | NA |
893- | QC,  |   | Quercetin: Prooxidant Effect and Apoptosis in Cancer |
- | Analysis, | Var, | NA |
- | in-vivo, | Var, | NA |
897- | QC,  |   | Anti- and prooxidant effects of chronic quercetin administration in rats |
- | in-vivo, | Nor, | NA |
898- | QC,  |   | Anti- and pro-oxidant activity of rutin and quercetin derivatives |
- | Analysis, | Var, | NA |
899- | QC,  |   | Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites |
- | in-vivo, | Var, | NA |
900- | QC,  |   | Quercetin Affects Erythropoiesis and Heart Mitochondrial Function in Mice |
- | in-vivo, | Nor, | NA |
908- | QC,  |   | Molecular Targets Underlying the Anticancer Effects of Quercetin: An Update |
- | Review, | NA, | NA |
906- | QC,  |   | The interplay between reactive oxygen species and antioxidants in cancer progression and therapy: a narrative review |
- | Review, | NA, | NA |
905- | QC,  |   | Anti- and pro-oxidant effects of quercetin in copper-induced low density lipoprotein oxidation. Quercetin as an effective antioxidant against pro-oxidant effects of urate |
- | Analysis, | NA, | NA |
904- | QC,  |   | Antioxidant and prooxidant effects of quercetin on glyceraldehyde-3-phosphate dehydrogenase |
- | Analysis, | NA, | NA |
902- | QC,  |   | Prooxidant activities of quercetin, p-courmaric acid and their derivatives analysed by quantitative structure–activity relationship |
- | Analysis, | NA, | NA |
901- | QC,  |   | Antioxidant/prooxidant effects of α-tocopherol, quercetin and isorhamnetin on linoleic acid peroxidation induced by Cu(II) and H2O2 |
- | Analysis, | Var, | NA |
2343- | QC,  |   | Pharmacological Activity of Quercetin: An Updated Review |
- | Review, | Nor, | NA |
3353- | QC,  |   | Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells |
- | in-vitro, | Oral, | KON | - | in-vitro, | Nor, | MRC-5 |
3355- | QC,  |   | Quercetin exhibits cytotoxicity in cancer cells by inducing two-ended DNA double-strand breaks |
- | in-vitro, | Cerv, | HeLa |
3348- | QC,  |   | Quercetin and iron metabolism: What we know and what we need to know |
- | Review, | NA, | NA |
3344- | QC,  |   | Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells |
- | in-vitro, | Nor, | hESC |
3372- | QC,  | FIS,  | KaempF,  |   | Anticancer Potential of Selected Flavonols: Fisetin, Kaempferol, and Quercetin on Head and Neck Cancers |
- | Review, | HNSCC, | NA |
3374- | QC,  |   | Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis |
- | Review, | Oral, | NA | - | Review, | AD, | NA |
3371- | QC,  |   | Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways |
- | in-vitro, | GBM, | T98G |
3369- | QC,  |   | Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects |
- | Review, | Pca, | NA |
3368- | QC,  |   | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
- | Review, | Var, | NA |
103- | RES,  | CUR,  | QC,  |   | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice |
- | vitro+vivo, | BC, | 4T1 |
871- | RES,  | CUR,  | QC,  |   | The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice |
- | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 |
924- | RES,  |   | Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells |
- | in-vitro, | OS, | U2OS | - | in-vitro, | Lung, | A549 |
882- | RES,  |   | Resveratrol: A Double-Edged Sword in Health Benefits |
- | Review, | NA, | NA |
883- | RES,  |   | Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy |
1391- | RES,  | BBR,  |   | Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells |
- | in-vitro, | Tong, | SCC25 |
1490- | RES,  |   | Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues |
- | Review, | Var, | NA |
2332- | RES,  |   | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
- | Review, | Var, | NA |
2650- | RES,  |   | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
- | Review, | Var, | NA |
2687- | RES,  |   | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
- | Review, | NA, | NA | - | Review, | AD, | NA |
2441- | RES,  |   | Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions |
- | Review, | Var, | NA |
3071- | RES,  |   | Resveratrol and Its Anticancer Effects |
- | Review, | Var, | NA |
3076- | RES,  |   | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
- | Review, | Var, | NA |
3078- | RES,  |   | The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment |
- | Review, | Pca, | NA |
3052- | RES,  |   | Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways |
- | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Bxpc-3 |
3055- | RES,  |   | Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets |
- | Review, | Var, | NA |
3054- | RES,  |   | Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line |
- | in-vitro, | Melanoma, | A375 |
3096- | RES,  |   | Identification of potential target genes of non-small cell lung cancer in response to resveratrol treatment by bioinformatics analysis |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
3093- | RES,  |   | Pro-Oxidant Effect of Resveratrol on Human Breast Cancer MCF-7 Cells is Associated with CK2 Inhibition |
- | in-vitro, | BC, | MCF-7 |
3092- | RES,  |   | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
- | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF-7 |
3026- | RosA,  |   | Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts |
- | in-vitro, | Nor, | NA |
3010- | RosA,  |   | Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation |
- | in-vitro, | Lung, | A549 | - | in-vivo, | NA, | NA |
3002- | RosA,  |   | Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols |
- | Review, | Var, | NA |
3005- | RosA,  |   | Nanoformulated rosemary extract impact on oral cancer: in vitro study |
- | in-vitro, | Laryn, | HEp2 |
3038- | RosA,  |   | Prooxidant action of rosmarinic acid: transition metal-dependent generation of reactive oxygen species |
- | in-vitro, | Nor, | NA |
3037- | RosA,  |   | Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation |
- | in-vitro, | Oral, | SCC9 | - | in-vitro, | Oral, | HSC3 |
1742- | RosA,  |   | Rosmarinic acid, a natural polyphenol, has a potential pro-oxidant risk via NADH-mediated oxidative DNA damage |
- | Analysis, | Var, | NA |
1743- | RosA,  |   | New insights into the competition between antioxidant activities and pro-oxidant risks of rosmarinic acid |
- | Analysis, | Var, | NA |
1744- | RosA,  |   | Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity |
- | Review, | Var, | NA |
1748- | RosA,  |   | The Role of Rosmarinic Acid in Cancer Prevention and Therapy: Mechanisms of Antioxidant and Anticancer Activity |
- | Review, | Var, | NA |
323- | Sal,  | SNP,  |   | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
1208- | SANG,  |   | Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region |
- | in-vitro, | OS, | NA |
1388- | Sco,  |   | Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells |
- | in-vitro, | CRC, | NA |
1403- | SDT,  | BBR,  |   | From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | LLC1 |
2536- | SDT,  |   | Sonodynamic Therapy: Rapid Progress and New Opportunities for Non-Invasive Tumor Cell Killing with Sound |
- | Review, | Var, | NA |
2549- | SDT,  |   | Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation |
- | Review, | Var, | NA |
1018- | Sel,  |   | Selenite-induced autophagy antagonizes apoptosis in colorectal cancer cells in vitro and in vivo |
- | vitro+vivo, | CRC, | HCT116 | - | vitro+vivo, | CRC, | SW480 |
1002- | Sel,  | Osi,  | Adag,  |   | Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference |
- | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H385 |
1017- | Sel,  |   | Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of β-catenin survival axis |
- | vitro+vivo, | CRC, | NA |
2552- | SFN,  | Chemo,  |   | Chemopreventive activity of sulforaphane |
- | Review, | Var, | NA |
3183- | SFN,  |   | Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1 |
- | in-vitro, | GBM, | NA |
2448- | SFN,  |   | Sulforaphane and bladder cancer: a potential novel antitumor compound |
- | Review, | Bladder, | NA |
1722- | SFN,  |   | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
- | Review, | Var, | NA |
1730- | SFN,  |   | Sulforaphane: An emergent anti-cancer stem cell agent |
- | Review, | Var, | NA |
1723- | SFN,  |   | Sulforaphane as a potential remedy against cancer: Comprehensive mechanistic review |
- | Review, | Var, | NA |
1494- | SFN,  | doxoR,  |   | Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model |
- | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
1455- | SFN,  |   | Sulforaphane Activates a lysosome-dependent transcriptional program to mitigate oxidative stress |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | 1321N1 |
- | in-vitro, | Bladder, | T24 |
1483- | SFN,  |   | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
- | in-vitro, | OS, | 143B | - | in-vitro, | Nor, | HEK293 | - | in-vivo, | OS, | NA |
1481- | SFN,  | docx,  |   | Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
1468- | SFN,  |   | Cellular responses to dietary cancer chemopreventive agent D,L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species |
- | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
1456- | SFN,  |   | Sulforaphane regulates cell proliferation and induces apoptotic cell death mediated by ROS-cell cycle arrest in pancreatic cancer cells |
- | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
1458- | SFN,  |   | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
- | Review, | Bladder, | NA |
1459- | SFN,  | Aur,  |   | Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway |
- | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HepG2 |
1460- | SFN,  |   | High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells |
- | in-vitro, | Lung, | NA |
1463- | SFN,  |   | Sulforaphane induces reactive oxygen species-mediated mitotic arrest and subsequent apoptosis in human bladder cancer 5637 cells |
- | in-vitro, | Bladder, | 5637 |
1464- | SFN,  |   | d,l-Sulforaphane Induces ROS-Dependent Apoptosis in Human Gliomablastoma Cells by Inactivating STAT3 Signaling Pathway |
- | in-vitro, | GBM, | NA |
1465- | SFN,  |   | TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells |
- | NA, | Bladder, | NA |
1466- | SFN,  |   | Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway |
- | vitro+vivo, | Thyroid, | FTC-133 |
1467- | SFN,  |   | Sulforaphane generates reactive oxygen species leading to mitochondrial perturbation for apoptosis in human leukemia U937 cells |
- | in-vitro, | AML, | U937 |
1480- | SFN,  |   | Sulforaphane Induces Cell Death Through G2/M Phase Arrest and Triggers Apoptosis in HCT 116 Human Colon Cancer Cells |
- | in-vitro, | CRC, | HCT116 |
1469- | SFN,  |   | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
1470- | SFN,  | Rad,  |   | Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Lung, | A549 | - | in-vitro, | lymphoma, | U937 |
1471- | SFN,  |   | ROS-mediated activation of AMPK plays a critical role in sulforaphane-induced apoptosis and mitotic arrest in AGS human gastric cancer cells |
- | in-vitro, | GC, | AGS |
1472- | SFN,  |   | Sulforaphane Inhibits Autophagy and Induces Exosome-Mediated Paracrine Senescence via Regulating mTOR/TFE3 |
- | in-vitro, | ESCC, | NA |
1474- | SFN,  |   | Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway |
- | in-vitro, | Colon, | SW480 |
1475- | SFN,  | Form,  |   | Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway |
- | in-vitro, | Cerv, | HeLa |
1476- | SFN,  | PDT,  |   | Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane |
- | in-vitro, | HNSCC, | NA |
1477- | SFN,  |   | Sulforaphane Induces Oxidative Stress and Death by p53-Independent Mechanism: Implication of Impaired Glutathione Recycling |
- | in-vitro, | OS, | MG63 |
- | in-vitro, | CRC, | HCT116 |
978- | SIL,  |   | A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment |
- | Review, | NA, | NA |
2410- | SIL,  |   | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
3301- | SIL,  |   | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
- | Review, | Var, | NA |
3306- | SIL,  | Rad,  |   | Radioprotective and radiosensitizing properties of silymarin/silibinin in response to ionizing radiation |
- | Review, | Var, | NA |
3309- | SIL,  |   | Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives |
- | Review, | NA, | NA |
3299- | SIL,  |   | Silymarin Effect on Mitophagy Pathway in the Human Colon Cancer HT-29 Cells |
- | in-vitro, | Colon, | HT29 |
3298- | SIL,  |   | Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells |
- | in-vitro, | BC, | MCF-7 |
3296- | SIL,  |   | Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway |
- | in-vitro, | Oral, | Ca9-22 | - | in-vivo, | Oral, | YD10B |
3292- | SIL,  | Fe,  |   | Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study |
- | in-vitro, | BC, | 4T1 | - | in-vivo, | BC, | 4T1 |
3290- | SIL,  |   | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
- | Analysis, | Var, | NA |
2362- | SK,  |   | RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide |
- | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA | - | in-vitro, | GBM, | U251 |
2355- | SK,  |   | Pharmacological properties and derivatives of shikonin-A review in recent years |
- | Review, | Var, | NA |
2230- | SK,  |   | Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer |
- | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
2229- | SK,  |   | Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways |
- | in-vitro, | Melanoma, | A375 |
2228- | SK,  |   | Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT15 | - | in-vivo, | NA, | NA |
2227- | SK,  |   | Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species |
- | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
- | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | Bel-7402 |
2221- | SK,  |   | Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression |
- | in-vitro, | Lung, | A549 |
2219- | SK,  |   | Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways |
- | in-vitro, | Nor, | HaCaT |
2415- | SK,  |   | Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways |
- | in-vivo, | Arthritis, | NA |
2416- | SK,  |   | Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells |
- | in-vitro, | Testi, | TCAM-2 |
2469- | SK,  |   | Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2 |
- | in-vitro, | Lung, | H1975 |
3040- | SK,  |   | Pharmacological Properties of Shikonin – A Review of Literature since 2002 |
- | Review, | Var, | NA | - | Review, | IBD, | NA | - | Review, | Stroke, | NA |
3041- | SK,  |   | Promising Nanomedicines of Shikonin for Cancer Therapy |
- | Review, | Var, | NA |
3045- | SK,  |   | Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2) |
- | in-vitro, | PC, | MIA PaCa-2 |
3047- | SK,  |   | Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway |
- | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
1280- | SK,  |   | Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells |
- | in-vitro, | GC, | AGS |
1284- | SK,  |   | Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy |
- | in-vitro, | Melanoma, | RPMI-8226 | - | in-vitro, | Melanoma, | U266 |
1312- | SK,  |   | Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells |
- | in-vitro, | OS, | 143B |
1346- | SK,  |   | An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | Hs683 |
1345- | SK,  |   | The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway |
- | in-vitro, | AML, | HL-60 |
1344- | SK,  |   | Novel multiple apoptotic mechanism of shikonin in human glioma cells |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | Hs683 | - | in-vitro, | GBM, | M059K |
1343- | SK,  |   | Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis |
- | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | A2780S |
1342- | SK,  |   | RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species |
- | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
2010- | SK,  |   | Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway |
- | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 | - | in-vitro, | Nor, | CCD19 |
2009- | SK,  |   | Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer |
- | in-vitro, | Bladder, | NA |
2008- | SK,  | Cisplatin,  |   | Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo |
- | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
2007- | SK,  |   | Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells |
- | in-vitro, | lymphoma, | U937 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | OS, | U2OS | - | NA, | Nor, | RPE-1 |
2190- | SK,  |   | Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway |
- | in-vitro, | HCC, | HCCLM3 |
2189- | SK,  |   | PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells |
- | in-vitro, | Melanoma, | NA |
2188- | SK,  |   | Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment |
- | Review, | Var, | NA |
2186- | SK,  |   | Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line |
- | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | HCCLM3 |
2210- | SK,  |   | Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway |
- | in-vitro, | BC, | MGC803 |
2203- | SK,  |   | Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation |
- | in-vitro, | Lung, | NA |
2202- | SK,  |   | Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification |
- | in-vitro, | Var, | NA |
2200- | SK,  |   | Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis |
- | in-vitro, | Thyroid, | CAL-62 | - | in-vitro, | Thyroid, | 8505C |
2199- | SK,  |   | Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis |
- | in-vitro, | GC, | NA |
2198- | SK,  |   | Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis |
- | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | 143B |
2197- | SK,  |   | Shikonin derivatives for cancer prevention and therapy |
- | Review, | Var, | NA |
2195- | SK,  |   | Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis |
- | in-vitro, | OS, | NA |
1050- | SK,  |   | Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation |
- | in-vitro, | Colon, | CT26 |
1073- | SK,  | Chemo,  |   | Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells |
- | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
1406- | SNP,  |   | The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition |
- | in-vivo, | Nor, | NA |
- | in-vitro, | Lung, | U1285 |
1908- | SNP,  |   | Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase |
- | in-vitro, | Lung, | A549 |
2538- | SNP,  | SDT,  | Z,  |   | Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment |
- | Study, | Var, | NA | - | vitro+vivo, | NA, | NA |
2835- | SNP,  | Gluc,  |   | Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake |
- | in-vitro, | Liver, | HepG2 |
2836- | SNP,  | Gluc,  |   | Glucose capped silver nanoparticles induce cell cycle arrest in HeLa cells |
- | in-vitro, | Cerv, | HeLa |
2288- | SNP,  |   | Silver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro Model |
- | Review, | Var, | NA |
2287- | SNP,  |   | Silver nanoparticles induce endothelial cytotoxicity through ROS-mediated mitochondria-lysosome damage and autophagy perturbation: The protective role of N-acetylcysteine |
- | in-vitro, | Nor, | HUVECs |
- | in-vitro, | Nor, | 3T3 |
335- | SNP,  | PDT,  |   | Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy |
- | Review, | NA, | NA |
341- | SNP,  |   | Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles |
- | in-vitro, | Liver, | HepG2 |
342- | SNP,  |   | Silver nanoparticles; a new hope in cancer therapy? |
- | Review, | NA, | NA |
344- | SNP,  |   | Cytotoxicity and ROS production of manufactured silver nanoparticles of different sizes in hepatoma and leukemia cells |
- | in-vitro, | Liver, | HepG2 |
346- | SNP,  | RSQ,  |   | Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment |
- | in-vivo, | Melanoma, | SK-MEL-28 | - | in-vivo, | Melanoma, | WM35 |
347- | SNP,  |   | The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future? |
- | Review, | NA, | NA |
- | in-vitro, | BC, | MCF-7 |
349- | SNP,  |   | Insight into the molecular mechanism, cytotoxic, and anticancer activities of phyto-reduced silver nanoparticles in MCF-7 breast cancer cell lines |
- | in-vitro, | BC, | MCF-7 |
350- | SNP,  |   | Cytotoxic and Apoptotic Effects of Green Synthesized Silver Nanoparticles via Reactive Oxygen Species-Mediated Mitochondrial Pathway in Human Breast Cancer Cells |
- | in-vitro, | BC, | MCF-7 |
353- | SNP,  |   | The mechanism of cell death induced by silver nanoparticles is distinct from silver cations |
- | in-vitro, | BC, | SUM159 |
355- | SNP,  |   | Cytotoxicity and Genotoxicity of Biogenic Silver Nanoparticles in A549 and BEAS-2B Cell Lines |
- | in-vitro, | Lung, | A549 | - | in-vitro, | NA, | BEAS-2B |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | Bladder, | HTB-22 |
322- | SNP,  | Cisplatin,  |   | Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin |
- | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
306- | SNP,  |   | Cancer Therapy by Silver Nanoparticles: Fiction or Reality? |
- | Analysis, | NA, | NA |
309- | SNP,  |   | Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells |
- | in-vitro, | NA, | A431 |
316- | SNP,  |   | Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells |
- | in-vitro, | BC, | MCF-7 |
320- | SNP,  |   | Silver nanoparticles induce endoplasmatic reticulum stress response in zebrafish |
- | vitro+vivo, | NA, | HUH7 |
324- | SNP,  | CPT,  |   | Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells |
- | in-vitro, | Cerv, | HeLa |
327- | SNP,  | MS-275,  |   | Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells |
- | in-vitro, | Lung, | A549 |
330- | SNP,  | Rad,  |   | Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs |
- | in-vitro, | GBM, | U251 |
381- | SNP,  |   | Silver Nanoparticles Exert Apoptotic Activity in Bladder Cancer 5637 Cells Through Alteration of Bax/Bcl-2 Genes Expression |
- | in-vitro, | Bladder, | 5637 |
384- | SNP,  |   | Dual functions of silver nanoparticles in F9 teratocarcinoma stem cells, a suitable model for evaluating cytotoxicity- and differentiation-mediated cancer therapy |
- | in-vitro, | Testi, | F9 |
- | in-vitro, | BC, | MCF-7 |
- | in-vitro, | Laryn, | HEp2 |
397- | SNP,  | GEM,  |   | Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment |
- | in-vitro, | Ovarian, | A2780S |
358- | SNP,  |   | Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer |
- | vitro+vivo, | Ovarian, | SKOV3 |
394- | SNP,  |   | Anticancer activity of Moringa oleifera mediated silver nanoparticles on human cervical carcinoma cells by apoptosis induction |
- | in-vitro, | Cerv, | HeLa |
393- | SNP,  |   | Green synthesized plant-based silver nanoparticles: therapeutic prospective for anticancer and antiviral activity |
- | in-vitro, | NA, | HCT116 |
390- | SNP,  |   | Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA |
388- | SNP,  |   | Apoptotic efficacy of multifaceted biosynthesized silver nanoparticles on human adenocarcinoma cells |
- | in-vitro, | BC, | MCF-7 |
385- | SNP,  |   | Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment |
- | in-vitro, | Hepat, | HepG2 | - | in-vitro, | Hepat, | WI38 |
357- | SNP,  |   | Hypoxia-mediated autophagic flux inhibits silver nanoparticle-triggered apoptosis in human lung cancer cells |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | L132 |
359- | SNP,  |   | Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells |
- | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
363- | SNP,  |   | Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis |
365- | SNP,  |   | Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species |
- | in-vitro, | Hepat, | HepG2 |
367- | SNP,  |   | Presence of an Immune System Increases Anti-Tumor Effect of Ag Nanoparticle Treated Mice |
- | in-vivo, | NA, | NA |
369- | SNP,  |   | Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis |
- | in-vitro, | Liver, | NA |
370- | SNP,  |   | Differential genotoxicity mechanisms of silver nanoparticles and silver ions |
- | in-vitro, | lymphoma, | TK6 |
371- | SNP,  |   | Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549 |
- | in-vitro, | Lung, | A549 |
373- | SNP,  |   | Cytotoxic Potential and Molecular Pathway Analysis of Silver Nanoparticles in Human Colon Cancer Cells HCT116 |
- | in-vitro, | Colon, | HCT116 |
374- | SNP,  |   | Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
375- | SNP,  | ALA,  |   | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
- | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
377- | SNP,  |   | Anticancer Action of Silver Nanoparticles in SKBR3 Breast Cancer Cells through Promotion of Oxidative Stress and Apoptosis |
- | in-vitro, | BC, | SkBr3 |
- | in-vitro, | NSCLC, | A549 |
1626- | STF,  | dietFMD,  |   | When less may be more: calorie restriction and response to cancer therapy |
- | Review, | Var, | NA |
1932- | TQ,  |   | Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis |
- | Review, | Var, | NA |
1936- | TQ,  |   | Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line |
- | in-vitro, | Ovarian, | CaOV3 | - | in-vitro, | Nor, | WRL68 |
1935- | TQ,  |   | Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis |
- | Review, | OS, | NA |
1934- | TQ,  |   | Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | C4-2B |
1933- | TQ,  |   | Thymoquinone: potential cure for inflammatory disorders and cancer |
- | Review, | Var, | NA |
2129- | TQ,  | doxoR,  |   | Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells |
- | in-vitro, | BC, | MCF-7 |
2135- | TQ,  |   | Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets |
- | in-vitro, | Nor, | HaCaT |
2127- | TQ,  |   | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways |
- | Review, | GBM, | NA |
2124- | TQ,  |   | Thymoquinone: an emerging natural drug with a wide range of medical applications |
- | Review, | Var, | NA |
2123- | TQ,  |   | Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma |
- | in-vitro, | lymphoma, | PEL |
2122- | TQ,  |   | Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer |
- | Review, | Var, | NA |
2121- | TQ,  |   | ROS">Thymoquinone Inhibits Tumor Growth and Induces Apoptosis in a Breast Cancer Xenograft Mouse Model: The Role of p38 MAPK and ROS |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
2120- | TQ,  |   | ROS-mediated_suppression_of_STAT3">Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3 |
- | in-vitro, | Melanoma, | A431 |
2119- | TQ,  |   | Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant |
- | Review, | Var, | NA |
2100- | TQ,  |   | Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant |
- | Review, | NA, | NA |
2095- | TQ,  |   | Review on the Potential Therapeutic Roles of Nigella sativa in the Treatment of Patients with Cancer: Involvement of Apoptosis |
- | Review, | Var, | NA |
2094- | TQ,  |   | Cytotoxicity of Nigella sativa Extracts Against Cancer Cells: A Review of In Vitro and In Vivo Studies |
- | Review, | Var, | NA |
2106- | TQ,  |   | Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy |
- | Review, | Var, | NA |
2108- | TQ,  |   | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
- | Review, | Var, | NA |
2084- | TQ,  |   | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
- | Review, | Var, | NA |
2109- | TQ,  |   | Thymoquinone Induces Mitochondria-Mediated Apoptosis in Acute Lymphoblastic Leukaemia in Vitro |
- | in-vitro, | ALL, | CEM |
2110- | TQ,  |   | Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells |
- | in-vitro, | HCC, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
2112- | TQ,  |   | Crude flavonoid extract of the medicinal herb Nigella sativa inhibits proliferation and induces apoptosis in breastcancer cells |
- | in-vitro, | BC, | MCF-7 |
1928- | TQ,  |   | Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
1929- | TQ,  |   | Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells |
- | in-vitro, | Bladder, | 5637 | - | in-vitro, | Bladder, | T24 |
1930- | TQ,  |   | Therapeutic implications and clinical manifestations of thymoquinone |
- | Review, | Var, | NA |
1931- | TQ,  | doxoR,  |   | Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms |
- | in-vivo, | AML, | NA |
3422- | TQ,  |   | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
- | Review, | Var, | NA |
3424- | TQ,  |   | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
- | Review, | Var, | NA |
3425- | TQ,  |   | Advances in research on the relationship between thymoquinone and pancreatic cancer |
3403- | TQ,  |   | A multiple endpoint approach reveals potential in vitro anticancer properties of thymoquinone in human renal carcinoma cells |
- | in-vitro, | RCC, | 786-O |
3411- | TQ,  |   | Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone |
- | Review, | Var, | NA |
3412- | TQ,  |   | Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of Jak2/STAT3 signaling pathway in human melanoma cells |
- | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vivo, | NA, | NA |
3413- | TQ,  |   | Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase |
- | in-vitro, | CRC, | HCT116 |
3414- | TQ,  |   | Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells |
- | in-vitro, | RCC, | Caki-1 |
3571- | TQ,  |   | The Role of Thymoquinone in Inflammatory Response in Chronic Diseases |
- | Review, | Var, | NA | - | Review, | Stroke, | NA |
2454- | Trip,  |   | Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ |
- | in-vitro, | HNSCC, | HaCaT | - | in-vivo, | NA, | NA |
2350- | UA,  |   | Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
- | Review, | Var, | NA |
3104- | VitC,  |   | Pro- and Antioxidant Effects of Vitamin C in Cancer in correspondence to Its Dietary and Pharmacological Concentrations |
3114- | VitC,  |   | Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression |
- | in-vitro, | AML, | NA |
3108- | VitC,  | QC,  |   | The role of quercetin and vitamin C in Nrf2-dependent oxidative stress production in breast cancer cells |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Lung, | A549 |
3107- | VitC,  |   | Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment |
- | Review, | Var, | NA |
3138- | VitC,  |   | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
- | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
- | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | AML, | PLB-985 |
3102- | VitC,  |   | Two Faces of Vitamin C—Antioxidative and Pro-Oxidative Agent |
- | Review, | Var, | NA | - | Review, | Stroke, | NA |
2485- | VitC,  | TACE,  |   | High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma |
- | Case Report, | HCC, | NA |
635- | VitC,  | VitK3,  |   | The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress |
- | in-vitro, | NA, | NA |
633- | VitC,  |   | Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment |
- | Analysis, | NA, | NA |
632- | VitC,  |   | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients |
- | Review, | NA, | NA |
631- | VitC,  |   | Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2 |
- | vitro+vivo, | Liver, | NA |
114- | VitC,  | QC,  |   | Chemoprevention of prostate cancer cells by vitamin C plus quercetin: role of Nrf2 in inducing oxidative stress |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | NA, | DU145 |
623- | VitC,  |   | The Involvement of Ascorbic Acid in Cancer Treatment |
- | Review, | NA, | NA |
627- | VitC,  |   | High-Dose Vitamin C for Cancer Therapy |
- | Review, | NA, | NA |
628- | VitC,  | Mg,  |   | Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation |
- | in-vivo, | Colon, | CT26 | - | in-vitro, | NA, | MCF-7 | - | in-vitro, | NA, | SkBr3 |
- | in-vitro, | NA, | NA |
596- | VitC,  |   | High-Dose Vitamin C in Advanced-Stage Cancer Patients |
- | Review, | NA, | NA |
597- | VitC,  | STF,  | GlucDep,  |   | The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness |
598- | VitC,  |   | Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly |
- | Review, | NA, | NA |
599- | VitC,  |   | Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment |
- | Review, | NA, | NA |
605- | VitC,  |   | Therapeutic Use of Vitamin C in Cancer: Physiological Considerations |
- | Review, | NA, | NA |
606- | VitC,  |   | Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer |
- | Review, | NA, | NA |
1216- | VitC,  |   | Ascorbic acid induces ferroptosis via STAT3/GPX4 signaling in oropharyngeal cancer |
- | in-vitro, | Laryn, | FaDu | - | in-vitro, | SCC, | SCC-154 |
2285- | VitK2,  |   | New insights into vitamin K biology with relevance to cancer |
- | Review, | Var, | NA |
2284- | VitK2,  |   | Menadione-induced DNA damage in a human tumor cell line |
- | in-vitro, | BC, | MCF-7 |
2283- | VitK2,  |   | Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response |
- | Review, | Var, | NA |
2281- | VitK2,  |   | The biological responses of vitamin K2: A comprehensive review |
- | Review, | Var, | NA |
2280- | VitK2,  |   | Vitamin K2 induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | AML, | HL-60 |
2279- | VitK2,  |   | Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways |
- | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | J82 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | L02 | - | in-vivo, | NA, | NA |
2278- | VitK2,  | VitK3,  | VitC,  |   | Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect |
- | Review, | Var, | NA |
1214- | VitK2,  |   | Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells |
- | in-vitro, | Bladder, | T24 | - | in-vitro, | Bladder, | J82 |
1816- | VitK2,  |   | Role of Vitamin K in Selected Malignant Neoplasms in Women |
- | Review, | Var, | NA |
1840- | VitK2,  |   | The mechanisms of vitamin K2-induced apoptosis of myeloma cells |
- | in-vitro, | Melanoma, | NA |
1829- | VitK2,  |   | Vitamin K: New insights related to senescence and cancer metastasis |
- | Review, | Var, | NA |
1824- | VitK2,  |   | Vitamin K and its analogs: Potential avenues for prostate cancer management |
- | Review, | Pca, | NA |
1817- | VitK2,  |   | Research progress on the anticancer effects of vitamin K2 |
- | Review, | Var, | NA |
1818- | VitK2,  |   | New insights on vitamin K biology with relevance to cancer |
- | Review, | Var, | NA |
1832- | VitK3,  | VitC,  |   | Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism |
- | in-vitro, | AML, | K562 |
1839- | VitK3,  |   | Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells |
- | in-vitro, | Pca, | NA |
1838- | VitK3,  | PDT,  |   | Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways |
- | in-vitro, | Cerv, | NA |
1837- | VitK3,  | VitC,  |   | Alpha-Tocopheryl Succinate Inhibits Autophagic Survival of Prostate Cancer Cells Induced by Vitamin K3 and Ascorbate to Trigger Cell Death |
- | in-vivo, | Pca, | NA |
1835- | VitK3,  | VitC,  |   | Potential therapeutic application of the association of vitamins C and K3 in cancer treatment |
- | Review, | Var, | NA |
1834- | VitK3,  | PDT,  |   | Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells |
- | in-vitro, | Melanoma, | A431 |
1828- | VitK3,  | VitC,  |   | Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C |
- | in-vivo, | GBM, | NA |
1827- | VitK3,  |   | A biophysical approach to menadione membrane interactions: relevance for menadione-induced mitochondria dysfunction and related deleterious/therapeutic effects |
- | Analysis, | Var, | NA |
1826- | VitK3,  |   | PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug |
- | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 |
1221- | Z,  |   | Unexpected zinc dependency of ferroptosis: what is in a name? |
- | Analysis, | Nor, | NA |
604- | ZO,  |   | Plant-Mediated Zinc Oxide Nanoparticles: Advances in the New Millennium towards Understanding Their Therapeutic Role in Biomedical Applications |
- | Review, | NA, | NA |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:275 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid